Medications · Hormone optimization

Testosterone

Bioidentical testosterone for hormone optimization.

Start a prescription All medications →
Testosterone molecular structure (Bioidentical androgen)

Why this needs to be personal

Why Personalized Testosterone

The FDA-approved testosterone dose schedules (cypionate 50 to 400 mg IM every 2 to 4 weeks, gel 1.62 percent applied daily) were calibrated for trial populations with hypogonadism, not for the specific man in front of the prescriber. Trial averages do not adjust for a starting total testosterone of 180 versus 320 ng/dL, a 38-year-old versus a 62-year-old, baseline hematocrit drifting toward 52 percent, an estradiol that rises sharply on aromatization, or a partner trying to conceive. Those are the variables that decide whether a given regimen lands as physiologic replacement or as a rolling supraphysiologic peak.

That is the work a compounding pharmacy does. The molecule is the same one the FDA reviewed. What changes is the fit: a 100 mg/mL cypionate concentration dosed twice weekly subcutaneously instead of the 200 mg/mL bolus every two weeks, a propionate preparation for a patient who needs shorter ester half-life around fertility-preservation cycles, a transdermal cream at a non-commercial strength for a man who runs hot on injectables, or a co-prescribed anastrozole troche and HCG sterile vial so estradiol control and intratesticular signaling are handled in the same protocol rather than three separate manufactured products.

This is the older arrangement that pre-dates mass manufacturing: a prescriber who knows the labs, a pharmacist who prepares the medication for that named patient, a chain of custody on every lot. Modern oversight, the same molecule, fit to the person.

In brief

Testosterone Explained

Testosterone is the body's main androgen hormone, the same molecule your testes (or, in women, ovaries and adrenal glands) make naturally. Doctors prescribe testosterone for men whose bodies no longer make enough (a condition called hypogonadism), and in carefully selected cases for post-menopausal women with low sexual desire.

There are many FDA-approved testosterone products: weekly or biweekly injections (cypionate, enanthate), longer-acting injections (Aveed), daily skin gels (AndroGel, Testim), nasal gel (Natesto), under-the-tongue or gum products (Striant), pellets implanted under the skin (Testopel), and a weekly self-injector (Xyosted) 2123.

RonanRx can also compound bioidentical testosterone when a patient needs something the manufactured products don't offer, a specific ester, a custom strength, a troche, a scrotal cream, or a formulation without a particular excipient 14. Testosterone is a Schedule III controlled substance, so it requires a prescription, careful recordkeeping, and ongoing monitoring of blood counts, PSA, and clinical response 1335.

At a glance

Quick Facts About Testosterone

Category
Endogenous androgen (anabolic steroid hormone); Schedule III controlled substance
Active ingredients
Testosterone (bioidentical); various esters, testosterone cypionate, testosterone enanthate, testosterone propionate, testosterone undecanoate
FDA-approved branded products
Numerous: AndroGel (transdermal gel), Testim (gel), Axiron (axillary solution), Fortesta/Vogelxo (gel), Striant (buccal), Testopel (subcutaneous pellets), Aveed (long-acting IM undecanoate), Natesto (intranasal), Xyosted (subcutaneous enanthate auto-injector), Depo-Testosterone (IM cypionate), Delatestryl (IM enanthate), Androderm (transdermal patch)
Routes studied in humans
Intramuscular (esters), subcutaneous (Xyosted, pellets, compounded cypionate), transdermal (gel, cream, patch), buccal, intranasal, oral undecanoate, troche (compounded)
Evidence posture
FDA-approved manufactured products for male hypogonadism are well-studied; landmark trials include the T-Trials (Snyder 2016), TRAVERSE cardiovascular outcomes (Lincoff 2023), TOM (Basaria 2010), and Endocrine Society / AUA practice guidelines (Bhasin 2018; Mulhall 2018)
FDA-approval status
Multiple FDA-approved manufactured products for primary or hypogonadotropic hypogonadism in men. Compounded variants are not FDA-approved but address established patient-specific clinical needs not met by the manufactured market.
Compounded under
503A, patient-specific prescription only; Schedule III controlled substance handling required
Compounded role
Distinct from 'essentially-a-copy' territory: patient-specific compounding addresses ester selection (cypionate vs enanthate vs propionate), custom strengths and concentrations, alternate dosage forms (troche, scrotal/transdermal cream, intranasal), excipient sensitivity, and dose individualization that the manufactured market does not offer.
Schedule
Schedule III controlled substance under the Controlled Substances Act; dispensing, recordkeeping, and refill limits per DEA

Prescription review

Patient-Specific Prescription Only

Testosterone on this page is a 503A compounded preparation. Every dose is made on a prescription, for a named patient, by a licensed pharmacist. It is not a stocked, mass-manufactured product.

  • Made to order, not off a shelf. No batch sits in a warehouse waiting for buyers. Your prescription is what triggers the prep.
  • Named-patient label. The bottle carries your name. The batch records carry your prescription.
  • Dose, strength, and route chosen for you. A prescriber who knows your chart decides what gets compounded, not a manufacturer who set the strength for a trial population.
  • Licensed pharmacist on the hook. A real person, with a license that can be pulled, signs off on every prep. State inspectors check the facility.
  • Compounded drugs are not FDA-approved. They should not be evaluated using branded-drug trial data. Availability varies by state and prescribed medication.
For prescribing doctors Offer this medication → For patients Find a partner clinic →

Real medicine, not gray market

How This Differs from a Research-Use-Only Website

A research-use-only website ships a vial from a warehouse. There is no prescription, no pharmacist, no facility inspection, and no way to recall the product if something is wrong with it. If the vial is mislabeled, contaminated, or under-potent, there is nobody whose license is at stake.

A 503A compounding pharmacy is the other thing. Your doctor writes the prescription. A licensed pharmacist, whose name is on the label, prepares the medicine in a facility the state inspects. If something goes wrong, there is a person and a license on the hook, and a documented chain of custody on every lot. That accountability is what makes it safe.

What it is

What is Testosterone?

Testosterone (17β-hydroxy-4-androsten-3-one) is the principal endogenous androgen in humans. In men, it is produced primarily by the Leydig cells of the testes under pulsatile pituitary luteinizing hormone (LH) stimulation; smaller amounts derive from adrenal androgen precursors. In women, testosterone is produced by the ovarian theca cells and by adrenal precursor conversion. Circulating testosterone is largely bound to sex hormone-binding globulin (SHBG) and albumin; free and weakly bound (bioavailable) testosterone drives most tissue effects.

Bioidentical testosterone, the same chemical entity as the endogenous hormone, has been available pharmaceutically since the 1930s, when it was synthesized and characterized concurrently by Butenandt and Ruzicka. Replacement therapy for hypogonadism has been in continuous clinical use since the 1950s 1.

The molecule itself is delivered in many forms: testosterone esters (cypionate, enanthate, propionate, undecanoate) that release free testosterone slowly after IM or SC injection; transdermal gels, patches, and creams; buccal bioadhesive tablets; intranasal gels; subcutaneous pellets; and oral undecanoate (in some markets) 3314. Each formulation is a different solution to the same delivery challenge: avoiding first-pass hepatic metabolism while producing physiologic serum levels.

How it works

How Testosterone Works

Class
Bioidentical androgen
First studied
1935 (synthesis)
Common forms
Injectable ester, cream, gel
Compounding category
503A, patient-specific prescription

Testosterone acts at the androgen receptor (AR), a nuclear hormone receptor expressed in muscle, bone, fat, prostate, brain, hair follicles, and many other tissues 61. Ligand binding triggers nuclear translocation and transcription of androgen-responsive genes 60. In some tissues, testosterone is converted to dihydrotestosterone (DHT) by 5α-reductase, DHT is a more potent AR agonist and drives prostate and external genital effects 63 64. In other tissues, testosterone is aromatized to estradiol by aromatase (CYP19A1), estradiol drives bone, lipid, and some sexual-function effects of testosterone in men 65.

Replacement therapy raises serum testosterone toward the mid-normal range, with downstream effects on muscle mass and strength, erythropoiesis, bone density, fat distribution, libido, erectile function, and mood 11. The T-Trials 3 demonstrated benefit across these domains in older men with low testosterone, with effect sizes that varied by indication. Reference ranges have been harmonized across the major cohort studies 49.

Importantly, exogenous testosterone suppresses pituitary LH and FSH through hypothalamic-pituitary-gonadal feedback. This shuts down endogenous testicular testosterone production and spermatogenesis. The clinical consequence is that men on TRT have markedly reduced fertility while on therapy, often with full or partial recovery after cessation 30 131.

Research history

Testosterone Research History

Testosterone was isolated and characterized in the 1930s by three independent groups (Butenandt, Ruzicka, and Laqueur), with Butenandt and Ruzicka sharing the 1939 Nobel Prize in Chemistry for sex-hormone work. Synthetic and esterified testosterone preparations (propionate, then enanthate and cypionate) entered clinical use through the 1940s and 1950s as injectable replacement therapy for primary hypogonadism 5542 45. Foundational biology of androgen action was synthesized by Mooradian's 1987 Endocrine Reviews piece, and the molecular dissection of the androgen receptor and its 5α-reductase / aromatase co-pathways was completed across the 1990s and 2000s 63 606162.

Subcutaneous pellet implants (Testopel), among the oldest still-marketed delivery forms, were rigorously pharmacokinetically characterized by Handelsman in 1990 and refined by Kelleher in 2001 and 2004 6869. The 1990s brought transdermal delivery. Testosterone scrotal patches preceded non-scrotal patches (Androderm), and then transdermal gels, AndroGel (FDA-approved 2000) and Testim, became dominant outpatient formulations 575052. Wang 2000 and Swerdloff 2000 characterized the pharmacokinetics of transdermal gel and established that controlled daily application produced physiologic levels with less peak-trough variability than esters 15164. Buccal bioadhesive (Striant, Wang 2004; Korbonits 2004) and oral undecanoate (in some markets) followed 17 146.

Population-level characterization of late-onset hypogonadism advanced in the 2000s through the European Male Aging Study (EMAS): Wu and colleagues published the operational symptom-plus-laboratory definition of late-onset hypogonadism in NEJM 2010 47 and Tajar's 2012 follow-up characterized the heterogeneity of primary, secondary, and compensated forms 48 43. Travison and Bhasin's 2017 harmonization of total testosterone reference ranges across four major cohorts (CARDIA, EMAS, FHS, Osteoporotic Fractures in Men Study) provided the cross-cohort 264, 916 ng/dL reference range now widely cited 54941.

The 2010s expanded the route palette. Aveed (testosterone undecanoate IM, FDA-approved 2014) gave 10-week dosing intervals 19. Natesto (intranasal gel, FDA-approved 2014) preserved spermatogenesis better than other formulations because brief intranasal pulses incompletely suppress LH 21. Xyosted (testosterone enanthate auto-injector for weekly SC dosing, FDA-approved 2018) addressed needle-anxiety and produced steadier serum levels than IM dosing 22 2023. Testopel pellets (3, 6 month duration) remain in use. Bachman and colleagues (2014) clarified that testosterone-induced erythropoiesis involves suppression of hepcidin and resetting of the EPO-hemoglobin set point, explaining the dose-dependent erythrocytosis quantified earlier by Coviello 2008 5924 29.

Cardiovascular safety dominated the 2010s clinical-evidence debate. Vigen 2013 (JAMA) reported observational excess mortality / MI / stroke in a Veterans Affairs cohort 10. Xu 2013 (BMC Medicine), Fernández-Balsells 2010 (JCEM), Borst 2015 (Am J Physiol), and Alexander 2017 (Am J Med) meta-analyzed the pre-TRAVERSE randomized data with varying conclusions ranging from no excess risk to suggestion of harm with transdermal routes. The TOM trial 9 was stopped early for excess CV events in frail older men 44. The FDA-mandated cardiovascular outcomes trial TRAVERSE 8 finally provided definitive randomized data: non-inferior for MACE, with increased atrial fibrillation, AKI, and pulmonary embolism. The TRAVERSE substudy program 39 extended the safety/benefit dataset across organ systems. Hudson's 2022 individual-participant-data meta-analysis (Lancet Healthy Longevity) integrated pre- and TRAVERSE-era trials 565846.

Parallel: the Testosterone Trials 3 established efficacy across sexual function, mood, walking distance, anemia, and bone in men with classical hypogonadism 5128. The T4DM trial 38 demonstrated reduction in incident type 2 diabetes when testosterone was added to lifestyle modification in overweight and obese men with prediabetes or screening-detected diabetes 40 27. For women, Davis's 2008 NEJM trial of transdermal testosterone for postmenopausal HSDD, the earlier Braunstein 2005 and Kingsberg 2007 patch studies, the Wierman 2014 Endocrine Society women's guideline, and the Davis 2019 Global Consensus / Islam 2019 Lancet D&E meta-analysis comprise the women's evidence base 16467.

Timeline

Testosterone Timeline

  1. 1935 Butenandt and Ruzicka independently synthesize testosterone from cholesterol; Laqueur isolates testosterone from bull testes
  2. 1939 Butenandt and Ruzicka share Nobel Prize in Chemistry for sex-hormone work
  3. 1953 Testosterone cypionate (Depo-Testosterone) introduced, long-ester depot injection becomes the workhorse of replacement therapy
  4. 1987 Mooradian, Morley, and Korenman publish 'Biological actions of androgens' Endocrine Reviews, foundational synthesis of androgen-receptor physiology before the molecular era 60
  5. 1989 Mendel publishes 'The free hormone hypothesis' Endocrine Reviews, formalizes the conceptual basis for bioavailable vs total testosterone in target-tissue exposure 66
  6. 1990 Handelsman publishes pharmacokinetics and pharmacodynamics of testosterone pellets in man, provides the PK basis for subcutaneous pellet replacement (Testopel) 67
  7. 1991 Andersson, Berman, Jenkins, and Russell publish Nature paper on 5α-reductase type 2 gene deletion in male pseudohermaphroditism, anchors the two-isoenzyme model of DHT biosynthesis 63
  8. 1992 Jenkins, Andersson, Imperato-McGinley, Wilson, and Russell publish genetic and pharmacological evidence for more than one human steroid 5α-reductase (JCI), completes the type 1 / type 2 isozyme dissection 64
  9. 1996 Bhasin et al publish landmark study in NEJM showing supraphysiologic testosterone increases muscle size and strength in normal men with or without exercise 12
  10. 1999 Behre et al publish phase I pharmacokinetics of intramuscular testosterone undecanoate in male hypogonadism 18
  11. 2000 FDA approves AndroGel (transdermal testosterone gel); Wang and Swerdloff publish pivotal pharmacokinetic and clinical-outcomes papers 1415
  12. 2000 Mauras publishes 'Estrogen suppression in males: metabolic effects' (JCEM), demonstrates that aromatase inhibition in men reproduces specific features of estrogen deficiency despite preserved testosterone, foundational for the testosterone-vs-estradiol dissection in men 65
  13. 2001 Bhasin et al publish testosterone dose-response relationships in healthy young men, Am J Physiol Endocrinol Metab 13
  14. 2001 Kelleher publishes influence of implantation site and track geometry on the extrusion rate and pharmacology of testosterone implants (Clin Endocrinol), refines clinical handling of subcutaneous pellets 68
  15. 2002 Heinlein and Chang publish two foundational Endocrine Reviews papers, 'AR coregulators: an overview' and 'The roles of ARs and androgen-binding proteins in nongenomic androgen actions', establishing the modern molecular model of AR signaling 6162
  16. 2003 FDA approves Striant (buccal bioadhesive testosterone tablet)
  17. 2004 Wang and Korbonits publish pharmacokinetic characterization of buccal testosterone (Striant) in hypogonadal men 1617
  18. 2004 Kelleher publishes testosterone release rate and duration of action of testosterone pellet implants (Clin Endocrinol), quantitative basis for the 3, 6 month pellet interval 69
  19. 2005 Braunstein publishes RCT of transdermal testosterone patch in women with HSDD after oophorectomy (Arch Intern Med), early controlled trial of testosterone in postmenopausal HSDD 51
  20. 2005 Calof et al publish meta-analysis of adverse events with testosterone replacement in middle-aged and older men 26
  21. 2007 Kingsberg publishes clinically meaningful benefit analysis of the testosterone patch in postmenopausal women with HSDD (J Sex Med), informs effect-size interpretation for women's HSDD trials 52
  22. 2007 Saad et al publish eight-year clinical experience with long-acting parenteral testosterone undecanoate 20
  23. 2008 Coviello et al publish graded-dose testosterone effects on erythropoiesis in young and older men, defines the dose-dependence of erythrocytosis risk 24
  24. 2008 Minnemann et al publish comparison of long-acting testosterone undecanoate vs enanthate 19
  25. 2008 Davis et al publish NEJM RCT of transdermal testosterone for postmenopausal women with low libido not taking estrogen, best-known women's HSDD efficacy trial 50
  26. 2010 Wu et al publish 'Identification of late-onset hypogonadism in middle-aged and elderly men' (EMAS, NEJM), operational symptoms-plus-laboratory criteria for diagnosis 47
  27. 2010 Fernández-Balsells et al publish JCEM systematic review and meta-analysis of adverse effects of testosterone therapy 55
  28. 2010 Basaria et al publish TOM trial (NEJM), stopped early for cardiovascular adverse events in frail older men receiving transdermal testosterone 9
  29. 2012 Tajar et al characterize primary, secondary, and compensated hypogonadism in aging men in the EMAS cohort (JCEM) 48
  30. 2013 Vigen et al publish JAMA observational analysis of testosterone therapy and CV events in a Veterans Affairs cohort 10
  31. 2013 Xu et al publish BMC Medicine meta-analysis of testosterone therapy and cardiovascular events 56
  32. 2013 Finkelstein et al publish NEJM gonadal-steroid suppression study clarifying the relative contributions of testosterone vs estradiol to body composition, strength, and sexual function in men 11
  33. 2014 Bachman et al publish 'Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin' (J Gerontol), mechanistic basis of testosterone-induced erythropoiesis 59
  34. 2014 FDA approves Aveed (long-acting testosterone undecanoate IM) and Natesto (intranasal testosterone gel)
  35. 2014 Wierman et al publish updated Endocrine Society clinical practice guideline on androgen therapy in women 29
  36. 2014, 2015 FDA issues safety communications requiring class-wide cardiovascular labeling changes and mandating the post-marketing TRAVERSE outcomes trial
  37. 2015 Borst et al publish American Journal of Physiology meta-analysis suggesting injection testosterone is safer than transdermal administration for cardiovascular events 57
  38. 2016 Snyder et al publish the Testosterone Trials primary results in NEJM, benefit in sexual function, walking distance, mood/depressive symptoms, and anemia in older men with classical hypogonadism 3
  39. 2016 Cunningham et al publish JCEM T-Trials sexual function paper, detailed psychosexual outcomes 44
  40. 2016 Rogol et al publish Natesto pivotal pharmacokinetic / efficacy data 21
  41. 2017 Travison, Bhasin, and colleagues publish harmonized reference ranges for circulating testosterone levels in men of four cohort studies (JCEM), establishes cross-cohort 264, 916 ng/dL range 49
  42. 2017 T-Trials substudy publications: Roy et al (anemia, JAMA Intern Med), Budoff et al (coronary plaque, JAMA), Resnick et al (cognition, JAMA); Snyder et al publish bone density results in JAMA Internal Medicine 45564
  43. 2017 Hembree and Endocrine Society colleagues publish updated guideline on endocrine treatment of gender-dysphoric/gender-incongruent persons (JCEM), defines testosterone dosing for masculinizing gender-affirming care 53
  44. 2017 Alexander et al publish Am J Med meta-analysis of cardiovascular risks of exogenous testosterone use 58
  45. 2018 FDA approves Xyosted (subcutaneous testosterone enanthate weekly auto-injector)
  46. 2018 Bhasin et al publish updated Endocrine Society Clinical Practice Guideline on testosterone therapy in men with hypogonadism 1
  47. 2018 Mulhall et al publish the AUA Guideline on evaluation and management of testosterone deficiency 2
  48. 2018 Ohlander et al publish review of erythrocytosis following testosterone therapy 25
  49. 2018 Snyder et al publish 'Lessons From the Testosterone Trials' (Endocrine Reviews) consolidating T-Trial findings 7
  50. 2018 Traustadóttir et al publish 3-year extension showing testosterone supplementation attenuates age-related decline in aerobic capacity (JCEM) 70
  51. 2019 Davis et al publish Global Consensus Position Statement on testosterone therapy for women; Islam et al publish Lancet D&E meta-analysis 2728
  52. 2019 Kaminetsky and Gittelman publish 52-week and 26-week Xyosted safety/efficacy studies 2223
  53. 2021 Wittert et al publish T4DM (Lancet Diabetes & Endocrinology), testosterone added to lifestyle modification reduced incidence of type 2 diabetes in overweight/obese men with prediabetes or screening-detected diabetes 38
  54. 2022 Hudson et al publish Lancet Healthy Longevity individual-participant-data meta-analysis on adverse cardiovascular events and mortality in men during testosterone treatment 46
  55. 2022 Coleman and colleagues publish WPATH Standards of Care for the Health of Transgender and Gender Diverse People, Version 8, current best-practice framework for gender-affirming testosterone use 54
  56. 2023 Lincoff et al publish TRAVERSE cardiovascular outcomes trial in NEJM, non-inferior for MACE; increased atrial fibrillation, AKI, and pulmonary embolism in the testosterone arm 8
  57. 2023 Pencina et al publish TRAVERSE anemia substudy (JAMA Netw Open), testosterone corrects anemia in hypogonadal men over 12 months 42
  58. 2023 Valderrábano et al publish testosterone replacement protocol in prostate cancer survivors (Andrology), supports cautious replacement in selected prostate-cancer-survivor populations 71
  59. 2024 TRAVERSE substudies published: Snyder et al on fractures (NEJM, increased fracture rate in testosterone arm), Bhasin et al on diabetes progression (JAMA Intern Med, no effect on prediabetes-to-diabetes progression), Bhasin et al on prostate risk and monitoring (JCEM), and Pencina et al on sexual function and hypogonadal symptoms (JCEM) 39404143

Natural role

Biological Role of Testosterone

Testosterone is the principal mediator of male sexual development and adult androgen-dependent physiology. During fetal life it drives Wolffian duct differentiation; at puberty it drives growth of the external genitalia, voice deepening, body hair, muscle and bone growth, and the establishment of adult sexual function. In adult men, testosterone maintains libido, erectile function, spermatogenesis (via intratesticular concentrations approximately 100-fold higher than serum), erythropoiesis, lean body mass, bone density, and mood 28.

In women, testosterone is a normal physiologic hormone, circulating concentrations approximately one-tenth of male levels, with established roles in sexual function, mood, and contributions to bone and muscle physiology. The Endocrine Society 29, Global Consensus Position Statement 27, and Islam 2019 Lancet Diabetes & Endocrinology meta-analysis address testosterone's role in post-menopausal women with hypoactive sexual desire dysfunction (HSDD) 28.

Endogenous testosterone declines with age in men (approximately 1, 2% per year after age 30), with a subset of men developing symptomatic late-onset hypogonadism. The Endocrine Society defines clinical hypogonadism as the combination of consistent symptoms plus unequivocally low morning total testosterone confirmed on a repeat measurement 1, rather than age-related decline alone 28.

Clinical contexts studied

Clinical Contexts for Testosterone

Primary or hypogonadotropic hypogonadism in men fda approved

FDA-approved indication for multiple manufactured testosterone products.

Testosterone replacement is FDA-approved for adult men with classical primary (testicular failure) or hypogonadotropic (pituitary or hypothalamic) hypogonadism. Diagnosis per Endocrine Society 2018 guideline (Bhasin) and AUA 2018 guideline (Mulhall) requires consistent symptoms plus unequivocally low morning total testosterone confirmed on a repeat measurement 12. Goal of therapy is to restore serum testosterone to the mid-normal range and ameliorate symptoms. The T-Trials 3 demonstrated benefit in sexual function, walking distance, mood, anemia, and bone density in older men with classical hypogonadism.

Branded product: AndroGel, Testim, Androderm, Striant, Testopel, Aveed, Natesto, Xyosted, Depo-Testosterone, Delatestryl, Axiron, Fortesta, Vogelxo

Cardiovascular safety in middle-aged and older men with hypogonadism well studied

Addressed by the FDA-mandated TRAVERSE cardiovascular outcomes trial.

TRAVERSE 8 found testosterone non-inferior to placebo for major adverse cardiovascular events over a mean 33-month follow-up. Treated men had higher rates of atrial fibrillation, acute kidney injury, and pulmonary embolism. The earlier TOM trial 9 had been stopped for an excess of cardiovascular events in frail older men on transdermal testosterone, and the Vigen 2013 JAMA observational analysis raised similar concern 10. The Budoff 2017 T-Trials substudy reported greater coronary noncalcified plaque-volume progression in the testosterone arm than placebo, though without an MI signal in the parent T-Trials 5.

Postmenopausal hypoactive sexual desire dysfunction (HSDD) well studied

Off-label in the United States; supported by international guidelines and meta-analysis.

The 2019 Global Consensus Position Statement (Davis) and the Islam 2019 Lancet Diabetes & Endocrinology meta-analysis of 36 RCTs support short-term use of testosterone in physiologic doses for postmenopausal women with HSDD, with measurable improvement in sexual events, desire, arousal, and orgasm 2728. The Endocrine Society 2014 guideline (Wierman) endorsed a trial in selected postmenopausal women with HSDD 29. No FDA-approved testosterone product exists for women in the United States; compounded preparations or off-label use of low-dose male products are the practical options. Long-term safety data beyond 24 months remain limited.

Effects on body composition and physical function in older men well studied

Well-studied in the T-Trials and Finkelstein gonadal-suppression studies.

Replacement to mid-normal range improves lean mass, strength, and walking distance in older men with classical hypogonadism (T-Trials, Snyder 2016 NEJM). Finkelstein 2013 NEJM established that testosterone drives lean-mass changes while estradiol (derived from testosterone via aromatization) drives fat-mass changes, providing the mechanistic basis for the role of aromatization in male androgen physiology 1213. Snyder 2017 (JAMA Intern Med) demonstrated increased volumetric bone density and strength on QCT in older men receiving testosterone for one year 3411.

Anemia of hypogonadism / anemia of aging well studied

Well-studied; demonstrated benefit in T-Trials anemia substudy.

Testosterone is a physiologic erythropoietic stimulus. The T-Trials anemia substudy and the Pencina 2023 hypogonadism anemia RCT demonstrated correction of anemia in hypogonadal men. The dose-response relationship of testosterone with hematocrit 24 underlies both the therapeutic effect on anemia and the adverse-event risk of erythrocytosis 7. Ohlander 2018 reviewed monitoring and management of treatment-emergent erythrocytosis 25.

Off-label use

Off-Label Uses of Testosterone

Postmenopausal HSDD in women well studied

Supported by international guidelines; no FDA-approved product for women in the US.

Use of low-dose testosterone (physiologic female-range serum levels) is supported by the 2019 Global Consensus Position Statement (Davis) and the Islam 2019 meta-analysis 2728. Compounded female-strength preparations or off-label fractional dosing of male products are used in practice 29. Monitor for androgenic adverse effects (acne, hirsutism, voice changes) and confirm serum levels remain in the female physiologic range.

Gender-affirming masculinizing therapy well studied

Used per WPATH and Endocrine Society transgender-care guidelines; not addressed in detail on this page.

Testosterone is the principal hormone of masculinizing gender-affirming therapy. Dosing, monitoring, and shared decision-making follow WPATH Standards of Care and the Endocrine Society guidelines on endocrine treatment of gender-incongruent persons 1. RonanRx compounded testosterone is dispensed in this context only on a patient-specific prescription from the patient's clinician; this page does not substitute for those guidelines.

Age-related decline without symptomatic hypogonadism emerging

Not recommended by Endocrine Society or AUA guidelines.

Treating age-related testosterone decline in the absence of consistent symptoms plus unequivocally low confirmed morning total testosterone is not recommended by the Endocrine Society 2018 guideline (Bhasin) or the AUA 2018 guideline (Mulhall) 12. Direct-to-consumer 'low-T' marketing has historically pushed therapy outside the guideline-supported population; RonanRx does not support that framing.

FDA-approved use

FDA-Approved Uses of Testosterone

BrandIndicationYearRoute
AndroGel Testosterone replacement for male hypogonadism 2000 Transdermal gel
Testim Testosterone replacement for male hypogonadism 2002 Transdermal gel
Androderm Testosterone replacement for male hypogonadism 1995 Transdermal patch
Striant Testosterone replacement for male hypogonadism 2003 Buccal bioadhesive tablet
Testopel Testosterone replacement for male hypogonadism 1972 Subcutaneous pellet implant
Depo-Testosterone Testosterone replacement for male hypogonadism 1979 Intramuscular (testosterone cypionate in oil)
Delatestryl Testosterone replacement for male hypogonadism 1953 Intramuscular (testosterone enanthate in oil)
Aveed Testosterone replacement for male hypogonadism 2014 Intramuscular (testosterone undecanoate)
Natesto Testosterone replacement for male hypogonadism 2014 Intranasal gel
Xyosted Testosterone replacement for male hypogonadism 2018 Subcutaneous auto-injector (testosterone enanthate)
Fortesta / Vogelxo Testosterone replacement for male hypogonadism 2010 Transdermal gel
Axiron Testosterone replacement for male hypogonadism 2010 Topical axillary solution
Jatenzo / Tlando Testosterone replacement for male hypogonadism 2019 Oral (testosterone undecanoate)

Numerous FDA-approved testosterone products are available across IM, SC, transdermal, buccal, intranasal, oral undecanoate, and pellet routes 1416. All are indicated for testosterone replacement in adult men with primary (testicular failure) or hypogonadotropic (pituitary or hypothalamic) hypogonadism 19. Diagnostic criteria per the Endocrine Society 2018 guideline (Bhasin) and AUA 2018 guideline (Mulhall) require consistent symptoms plus unequivocally low morning total testosterone confirmed on a repeat measurement 12.

No FDA-approved testosterone product exists for women in the United States 2122. Postmenopausal HSDD use is supported by international guidelines 27 and meta-analysis 28 but is off-label in US practice.

Compounded use

Compounded Testosterone (503A)

Compounded testosterone occupies a long-standing legitimate role under 503A that is meaningfully distinct from typical 'essentially-a-copy' compounding. The manufactured market is wide but not exhaustive: it offers cypionate and enanthate IM (commonly 200 mg/mL), undecanoate IM (Aveed, fixed-strength prefilled), a narrow band of gel concentrations, a single buccal product, a single intranasal product, and pellets at a fixed strength. Patient-specific compounding addresses needs the manufactured market does not, alternative esters (propionate for shorter-action profiles), custom strengths (subphysiologic doses for women's HSDD; intermediate strengths for titration), alternative dosage forms (troches, scrotal cream, transdermal cream at custom concentrations), and excipient-free or excipient-substituted preparations.

Per FDA guidance on compounded copies of approved drugs, the prescribing clinician documents the patient-specific clinical reason 34. For testosterone the documented reasons are typically formulation/route the manufactured market does not provide (troche, scrotal cream, female-physiologic strength), ester preference based on past tolerability or PK characteristics, or excipient sensitivity. Routine substitution of a compounded cypionate vial for a manufactured cypionate vial without a documented clinical reason is not the appropriate framing.

Testosterone is a Schedule III controlled substance. Every compounded testosterone prescription is dispensed under DEA recordkeeping requirements for Schedule III drugs, with patient-specific prescription authorization, controlled-substance ordering, locked storage, and full chain-of-custody documentation 351.

Formulations and routes

Testosterone Formulations and Routes

FormConcentrationDescription
Testosterone cypionate injection (IM or SC) 100 mg/mL, 200 mg/mL (custom strengths available) Long-ester depot in cottonseed oil (or alternative oil for compounded). Subcutaneous administration is now commonly used in addition to IM; smaller more frequent SC doses produce steadier serum levels than larger IM doses every 2 weeks.
Testosterone enanthate injection (IM or SC) 100 mg/mL, 200 mg/mL Long-ester depot in sesame oil (or alternative). Pharmacokinetics similar to cypionate; SC weekly dosing studied formally in the Xyosted development program.2223
Testosterone propionate injection 100 mg/mL Short-ester depot for IM or SC use; frequent injection interval (every 1, 3 days). Compounded use is uncommon outside specific clinical scenarios.
Testosterone transdermal cream (compounded) 1%, 2%, 10%, custom Daily application to skin (scrotal or non-scrotal, per prescription). Used when the manufactured gel concentrations are not appropriate. Scrotal application gives higher absorption per mg than non-scrotal.
Testosterone troche (compounded) Custom, typical 5, 50 mg per troche Sublingual / buccal slow-dissolve troche. Bypasses first-pass metabolism; alternative to the manufactured buccal bioadhesive product for patients who tolerate troche but not the Striant adhesive matrix.
Testosterone intranasal gel (compounded variant) Custom Manufactured Natesto provides intranasal gel at a fixed concentration; compounded intranasal preparations may be dispensed for documented patient-specific need outside that product's range.21
Testosterone undecanoate (oral or IM) Oral: 40 mg/capsule (Jatenzo) or 200 mg/capsule (Tlando); IM: Aveed 750 mg/3 mL prefilled Manufactured oral undecanoate is FDA-approved for hypogonadism; bypasses first-pass via lymphatic absorption. Aveed IM gives ~10-week dosing intervals.192018
Testosterone subcutaneous pellet (Testopel) 75 mg per pellet, implanted in subcutaneous fat Manufactured pellets implanted in the subcutaneous tissue of the hip or buttock. Steady-state release over 3, 6 months.

Routes used in published literature: intramuscular, subcutaneous, transdermal, topical, buccal, intranasal, oral, sublingual, troche.

Dosing

Testosterone Dosing

RoutePopulationRangeDurationStudy type
Intramuscular or subcutaneous Adult men with classical hypogonadism, testosterone cypionate or enanthate Typical replacement: 50, 100 mg weekly SC or 100, 200 mg every 1, 2 weeks IM, titrated to mid-normal range trough total testosterone (approximately 400, 600 ng/dL on a level drawn before the next dose) Indefinite while clinically beneficial and tolerated Endocrine Society 2018 guideline; AUA 2018 guideline; mirrored by long-standing labeled regimens12
Subcutaneous (Xyosted) Adult men with hypogonadism, manufactured weekly auto-injector Starting 75 mg SC weekly, titration to 50, 100 mg weekly based on serum total testosterone two weeks after the most recent dose Indefinite while clinically beneficial Pivotal phase III safety and efficacy program (Kaminetsky 2019; Gittelman 2019)2223
Intramuscular (long-acting undecanoate, Aveed) Adult men with hypogonadism 750 mg IM on day 0, week 4, then every 10 weeks; deep gluteal injection administered under REMS observation due to risk of pulmonary oil microembolism / anaphylaxis Indefinite while clinically beneficial Manufactured FDA-approved regimen; Minnemann 2008; Saad 20071920
Transdermal gel (manufactured products) Adult men with hypogonadism Daily application: AndroGel 1.62%, 20.25 to 81 mg testosterone per day (1 to 4 pump actuations); Testim 1%, 5 to 10 g gel daily (50, 100 mg testosterone); Fortesta 2%, 40, 70 mg per day; Axiron 2% solution, 60, 120 mg per day axillary Indefinite while clinically beneficial Wang 2000 pivotal pharmacokinetic and clinical-outcomes data; Swerdloff 2000 long-term PK1415
Buccal (Striant) Adult men with hypogonadism 30 mg buccal tablet applied to gum twice daily (every 12 hours) Indefinite while clinically beneficial Wang 2004 and Korbonits 2004 pharmacokinetic data1617
Intranasal (Natesto) Adult men with hypogonadism 11 mg per nostril three times daily (total 33 mg/day) Indefinite while clinically beneficial Rogol 2016 pivotal pharmacokinetic / efficacy data21
Subcutaneous pellet (Testopel) Adult men with hypogonadism Typically 6, 12 pellets (450, 900 mg total) implanted every 3, 6 months Indefinite while clinically beneficial Long-standing labeled regimen; reviewed in Nieschlag 2006 and Endocrine Society 2018 guideline133
Transdermal cream or troche (compounded) Postmenopausal women, HSDD Target physiologic female range: typically 0.5, 5 mg testosterone per day (cream or troche) Trial of therapy 3, 6 months; reassess sexual function and androgenic adverse effects; long-term safety beyond 24 months not established Global Consensus Position Statement (Davis 2019); Islam 2019 Lancet D&E meta-analysis; Endocrine Society 2014 women's guideline (Wierman)272829

Doses listed reflect FDA-labeled regimens and published clinical-trial protocols, not RonanRx prescribing recommendations. The prescribing physician selects formulation, route, and starting dose based on the patient's clinical context (severity of hypogonadism, prior tolerability, fertility goals, formulation preference, prostate and CV risk profile, and shared decision-making) 1.

Practical considerations across routes: IM cypionate/enanthate every 1, 2 weeks produces the largest peak-trough excursions; subcutaneous weekly dosing reduces those excursions and is now common practice 1. Long-acting undecanoate (Aveed) requires REMS-program observation. Transdermal gels require attention to inter-personal transfer (washing hands, covering treated skin around women and children). Natesto's three-times-daily regimen better preserves LH/FSH and spermatogenesis than other routes 21, a fertility-relevant consideration. Pellets give the longest interval but require an in-office procedure.

Targeting mid-normal range (commonly serum total testosterone 400, 700 ng/dL on a trough draw for IM/SC routes; mid-morning for gels) is the standard end-point 2. Patient-reported symptom response, libido, energy, mood, erectile function, is weighted alongside the laboratory level.

Doses listed are literature context, not patient instructions. Dosing decisions are made by the prescribing doctor and tailored to the individual patient.

Safety

Testosterone Safety

Safety overview

Testosterone safety has been characterized over decades of clinical use plus, more recently, large randomized trial programs. The most clinically important on-therapy adverse events are dose-dependent erythrocytosis (rise in hematocrit; Coviello 2008 established the dose-response, Ohlander 2018 reviewed management), suppression of spermatogenesis with reduced fertility while on therapy 30, modest fluid retention and acne, and, at supraphysiologic doses, gynecomastia from aromatization to estradiol 2531.

Cardiovascular safety is the area of largest historical controversy. TRAVERSE 8 is the FDA-mandated cardiovascular outcomes RCT and the highest-quality randomized data available: testosterone was non-inferior to placebo for MACE over a mean 33-month follow-up. Treated men had higher rates of atrial fibrillation, acute kidney injury, and pulmonary embolism. Older signals from TOM 9 and observational analyses 10 had raised concern; TRAVERSE addressed but did not eliminate cardiovascular risk discussion. The Budoff 2017 T-Trials substudy reported greater coronary noncalcified plaque-volume progression in the testosterone arm than placebo over 12 months in older men with low testosterone 5.

Prostate safety: testosterone replacement is contraindicated in men with active prostate cancer or breast cancer. PSA monitoring at baseline and on therapy is standard per Endocrine Society and AUA guidelines 1. The 'androgen-adequacy' framing 32 has largely replaced the older 'testosterone drives prostate cancer' narrative for men without active disease, though caution and urologic involvement remain appropriate in men with PSA elevation or prior prostate cancer history 2426.

Other considerations include sleep apnea exacerbation in susceptible men, mood and behavior effects, and, with supraphysiologic dosing, hepatotoxicity (primarily a concern with 17-α-alkylated oral anabolic steroids, not bioidentical testosterone esters; Aveed carries a specific warning for pulmonary oil microembolism / anaphylaxis at the time of injection) 2.

Contraindications

Testosterone replacement is contraindicated in: active prostate cancer or breast cancer in men; pregnancy (testosterone is a teratogen, virilization of a female fetus); known hypersensitivity to testosterone or formulation excipients; uncorrected severe erythrocytosis (hematocrit above the threshold defined by the prescribing clinician, commonly >54%); severe untreated obstructive sleep apnea; severe uncompensated heart failure; and in men actively trying to achieve fertility unless an alternative regimen (HCG, clomiphene, or selective estrogen receptor modulator strategy) is selected instead 25.

Relative contraindications and cautions per the Endocrine Society 2018 guideline (Bhasin) and AUA 2018 guideline (Mulhall) include unevaluated prostate nodule or PSA elevation, prior thromboembolic disease, and prior major adverse cardiovascular event within recent months 12. Aveed has a REMS-required observation period after each injection due to pulmonary oil microembolism / anaphylaxis risk.

Drug interactions

Testosterone is metabolized hepatically; clinically relevant drug-drug interactions are limited compared with many other pharmacotherapies. Concomitant warfarin may require closer INR monitoring (testosterone can potentiate anticoagulant effect). Insulin and oral hypoglycemics may need dose adjustment in men whose glycemic control improves on replacement. Concomitant corticosteroids increase the risk of fluid retention. Aromatase inhibitors (anastrozole, letrozole) reduce conversion of testosterone to estradiol and may be co-prescribed in selected scenarios; concomitant 5α-reductase inhibitors (finasteride, dutasteride) reduce DHT conversion 1.

Transdermal product-specific consideration: inter-personal transfer of gel to women or children produces virilization risk. Patients are counseled to wash hands after application and to cover the treated area until absorbed.

Adverse events

Across the T-Trials and TRAVERSE program, on-therapy adverse events most commonly attributable to testosterone include: erythrocytosis (dose-dependent; Coviello 2008 quantified the dose-response, Ohlander 2018 reviewed monitoring and management), acne and oily skin, fluid retention, breast tenderness or mild gynecomastia, and, in some men, sleep-apnea exacerbation 2425. Reduced fertility from suppression of LH/FSH and spermatogenesis is consistent across formulations except partially for intranasal Natesto 21.

In TRAVERSE 8, the testosterone arm had higher rates of atrial fibrillation, acute kidney injury, and pulmonary embolism than placebo, with non-inferiority for MACE. The TOM trial 9 was stopped early for excess cardiovascular adverse events in frail older men. Calof 2005 meta-analyzed adverse events across earlier randomized trials of replacement in middle-aged and older men and identified elevated rates of erythrocytosis and PSA increase but not consistently elevated rates of prostate cancer detection 26.

Site-specific adverse events: IM injection, local pain, occasional sterile abscess; SC injection (Xyosted, compounded SC cypionate/enanthate), local irritation; gels, skin irritation, transfer risk; buccal, gum irritation, dysgeusia; intranasal, rhinorrhea, epistaxis; pellets, extrusion, infection at implant site; Aveed, REMS-monitored risk of pulmonary oil microembolism and anaphylaxis 23.

Monitoring

Monitoring Testosterone Therapy

Baseline assessment (per Endocrine Society 2018 / AUA 2018): morning total testosterone confirmed on a repeat measurement; SHBG with calculated or measured free testosterone where SHBG is suspected to be altered; LH and FSH (to differentiate primary vs secondary hypogonadism); complete blood count (baseline hematocrit); PSA and digital rectal exam in age-appropriate men (typically ≥40 years) with prostate-cancer risk discussion; lipid panel and HbA1c; fertility-goal counseling; symptom inventory 1.

On-therapy monitoring: serum total testosterone 3, 6 months after initiation and after any dose change, with subsequent annual reassessment if stable 2. Timing of the draw depends on formulation, trough (just before next dose) for IM/SC esters; 2, 8 hours after application for gels; mid-cycle for pellets. Hematocrit at baseline, 3, 6 months, 12 months, and annually thereafter; dose reduction or temporary hold if hematocrit exceeds the threshold defined by the prescribing clinician (commonly 54%) per Ohlander 2018 25.

PSA at 3, 12 months after initiation and annually thereafter in age-appropriate men. Symptom reassessment at each visit. Patients should report new-onset chest pain, dyspnea, leg swelling, or stroke-like symptoms promptly, particularly in light of the TRAVERSE atrial-fibrillation and PE signals 8.

Special populations

Testosterone in Special Populations

Pregnancy

Testosterone is teratogenic, exposure during pregnancy can produce virilization of a female fetus. Testosterone is contraindicated in pregnancy. Female partners of men using transdermal testosterone gel are counseled regarding transfer risk; covered application sites and hand-washing reduce transfer 1.

Lactation

Testosterone is contraindicated in women who are breastfeeding.

Pediatric

Pediatric and adolescent use is restricted to specialty endocrinology contexts (constitutional delay of puberty, congenital hypogonadotropic hypogonadism, gender-affirming care under specialty guidance). Not addressed in detail on this page.

Geriatric

Older men with classical hypogonadism benefit across sexual-function, walking-distance, mood, anemia, and bone-density domains per the T-Trials 3. The TRAVERSE trial enrolled men aged 45, 80 with elevated CV risk; testosterone was non-inferior for MACE but increased atrial fibrillation, AKI, and PE 58. The TOM trial signal 9 of excess CV events in frail older men remains relevant to risk discussion in that population 46.

Evidence quality

Testosterone Evidence Quality

Evidence for testosterone replacement in classical male hypogonadism is among the strongest in endocrinology 4843 42. Multiple FDA-approved manufactured products span IM, SC, transdermal, buccal, intranasal, and pellet routes, each supported by pivotal pharmacokinetic and clinical-outcomes programs 14. The Endocrine Society 2018 (Bhasin) and AUA 2018 (Mulhall) guidelines, together with the EMAS-derived diagnostic operationalization 47 and Travison 2017 harmonized reference ranges, provide the consensus diagnostic and therapeutic framing 4941.

The Testosterone Trials 3 are the highest-quality multi-domain randomized program in older men with classical hypogonadism 744. TRAVERSE 8 is the FDA-mandated cardiovascular outcomes RCT and the definitive randomized cardiovascular-safety data set in men with hypogonadism plus elevated CV risk; its substudy program 39 extends the safety/benefit dataset across organ systems 40. T4DM 38 is the largest randomized examination of testosterone in metabolic prevention 4556.

Pre-TRAVERSE cardiovascular safety was characterized by competing meta-analyses with heterogeneous conclusions: Calof 2005 (no consistent prostate-cancer excess), Fernández-Balsells 2010 (broad AE inventory), Xu 2013 (suggestion of CV risk), Borst 2015 (route-dependent CV risk with transdermal disadvantage), and Alexander 2017 (no consistent excess across pre-2017 RCTs) 55 5851. Hudson 2022 (Lancet Healthy Longevity) integrated individual-patient data including TRAVERSE-era trials 46.

For women, evidence is more limited and route-specific. Davis 2008 (NEJM) was the largest single RCT of transdermal testosterone for postmenopausal HSDD; earlier supporting RCTs include Braunstein 2005 and Kingsberg 2007 on the testosterone patch 575052. The Global Consensus Position Statement 27 and Islam 2019 Lancet D&E meta-analysis (8480 women, 36 RCTs) support short-term physiologic-dose testosterone for postmenopausal HSDD; long-term safety beyond 24 months is not established 2628. No FDA-approved testosterone product exists for women in the United States 676869. For gender-affirming care, the Endocrine Society 2017 guideline (Hembree) and WPATH Standards of Care Version 8 54 define current best practice 1253.

Evidence specifically supporting compounded preparations is observational and indirect; compounding is justified by patient-specific clinical need for formulations, strengths, or routes that the manufactured market does not offer 1.

Major studies

Major Testosterone Clinical Studies

StudyDesignParticipantsDurationFinding
TRAVERSE, Cardiovascular Safety of Testosterone-Replacement Therapy (Lincoff 2023 NEJM) Phase IV randomized double-blind placebo-controlled FDA-mandated cardiovascular outcomes trial 5246 Mean 33 months Testosterone non-inferior to placebo for major adverse cardiovascular events; increased atrial fibrillation, acute kidney injury, and pulmonary embolism in the testosterone arm 8
The Testosterone Trials, Effects of Testosterone Treatment in Older Men (Snyder 2016 NEJM) Coordinated set of seven double-blind placebo-controlled trials in older men with classical hypogonadism 790 12 months Improvement in sexual function, walking distance, mood and depressive symptoms, and anemia; smaller effects in vitality and cognition 3
T-Trials Bone Substudy (Snyder 2017 JAMA Internal Medicine) Substudy of T-Trials, QCT bone density and strength 211 12 months Increased volumetric bone density and estimated bone strength in spine and hip on testosterone vs placebo 4
T-Trials Coronary Plaque Substudy (Budoff 2017 JAMA) Substudy of T-Trials, coronary CT angiography 170 12 months Greater progression of coronary noncalcified plaque volume on testosterone than placebo; no MACE imbalance in the parent T-Trials 5
T-Trials Cognition Substudy (Resnick 2017 JAMA) Substudy of T-Trials, cognitive testing in men with age-associated memory impairment 493 12 months No significant effect on delayed paragraph recall or other primary cognitive endpoints 6
Lessons From the Testosterone Trials (Snyder 2018 Endocrine Reviews) Narrative synthesis of the T-Trials program — Synthesis Consolidated benefit/risk picture across sexual function, mood, vitality, bone, anemia, plaque, and cognition substudies 7
TOM, Adverse Events Associated With Testosterone Administration (Basaria 2010 NEJM) Randomized double-blind placebo-controlled trial of transdermal testosterone gel in older men with mobility limitations 209 Stopped early after 6 months Trial stopped for excess cardiovascular adverse events in the testosterone arm in frail older men 9
Gonadal Steroids and Body Composition (Finkelstein 2013 NEJM) Goserelin-induced gonadal suppression with add-back testosterone ± anastrozole in healthy men 400 16 weeks Testosterone primarily drives lean-mass changes; estradiol (derived from aromatization) primarily drives fat-mass changes, established the relative contribution of T vs E2 to male physiology 11
Testosterone Dose-Response in Healthy Young Men (Bhasin 2001) Randomized open-label dose-response study with gonadal suppression and graded testosterone enanthate add-back 61 20 weeks Linear dose-response of fat-free mass, leg strength, and hemoglobin with testosterone dose; established the dose-effect curve carried into clinical replacement and supraphysiologic ranges 13
Supraphysiologic Testosterone in Normal Men (Bhasin 1996 NEJM) Randomized placebo-controlled trial of testosterone enanthate 600 mg/week ± exercise in normal men 43 10 weeks Supraphysiologic testosterone increased fat-free mass, muscle size, and strength even without exercise, defined the upper end of androgenic anabolic dose-response in humans 12
Effects of Graded Doses of Testosterone on Erythropoiesis (Coviello 2008 JCEM) Gonadal-suppression dose-response in young and older men 61 20 weeks Dose-dependent rise in hemoglobin and hematocrit; older men had greater erythropoietic response per dose than young men, provides the mechanistic basis for the erythrocytosis warning at higher replacement doses 24
Erythrocytosis Following Testosterone Therapy (Ohlander 2018) Narrative review — Review Reviewed prevalence, mechanism, and management; provided the 50, 54% hematocrit threshold framework now used in clinical guidelines 25
Vigen, Testosterone Therapy and Mortality / MI / Stroke (Vigen 2013 JAMA) Retrospective observational cohort in a Veterans Affairs population 8709 Mean 27 months Observational signal of increased CV events on testosterone; methodology debated; superseded as primary CV-risk evidence by TRAVERSE 10
Calof, Adverse Events Meta-Analysis (Calof 2005) Meta-analysis of randomized placebo-controlled trials of testosterone replacement in middle-aged and older men 19 trials, ~650 patients Up to 3 years Elevated rates of erythrocytosis and PSA increase on testosterone vs placebo; no consistent excess of detected prostate cancer 26
Endocrine Society Clinical Practice Guideline, Testosterone in Men with Hypogonadism (Bhasin 2018) Clinical practice guideline — Synthesis Diagnostic, therapeutic, and monitoring recommendations for testosterone replacement in adult men 1
AUA Guideline, Evaluation and Management of Testosterone Deficiency (Mulhall 2018) Clinical practice guideline — Synthesis Urology-focused recommendations on diagnosis, therapy, and monitoring 2
Transdermal Testosterone Gel, Pivotal RCT (Wang 2000 JCEM) Randomized open-label clinical trial of AndroGel in hypogonadal men — 180 days Daily transdermal gel produced physiologic testosterone levels and improved sexual function, mood, muscle strength, and body composition 14
Long-Term Transdermal Testosterone Gel Pharmacokinetics (Swerdloff 2000 JCEM) Open-label long-term PK study — Up to 6 months Stable serum testosterone over months of daily transdermal gel application; route established as a long-term option 15
Natesto Intranasal Gel, Pivotal Study (Rogol 2016 Andrology) Phase III open-label trial in hypogonadal men — 90 days TID intranasal gel normalized testosterone; better preservation of LH/FSH and spermatogenesis than other formulations 21
Xyosted Subcutaneous Testosterone Enanthate (Kaminetsky 2019; Gittelman 2019) Phase III safety and efficacy programs — 26 and 52 weeks Weekly SC auto-injection produced steady serum testosterone with acceptable safety profile; basis for FDA approval (2018) 2223
Striant Buccal Testosterone (Wang 2004 and Korbonits 2004 JCEM) Pharmacokinetic comparison studies — Weeks Twice-daily buccal bioadhesive tablet produced physiologic testosterone levels comparable to transdermal patch 1617
Testosterone Undecanoate IM, Phase I and Long-Term (Behre 1999; Minnemann 2008; Saad 2007) Phase I pharmacokinetics and long-term registry/comparison studies — Weeks to years Long-acting undecanoate IM gives stable testosterone with ~10-week injection intervals; basis for Aveed (US) and Nebido (ex-US) 181920
Testosterone for Women, Global Consensus and Meta-Analysis (Davis 2019; Islam 2019) Position statement and meta-analysis of 36 RCTs 8480 women (Islam) 12 weeks to 2 years Short-term physiologic-dose testosterone improves sexual events, desire, arousal, orgasm, and pleasure in postmenopausal women with HSDD; long-term safety beyond 24 months not established 2728
Recovery of Spermatogenesis after Testosterone or AAS (McBride 2016; Ramasamy 2015) Reviews and clinical series — Months to years post-cessation Spermatogenesis suppression is consistent during exogenous testosterone; recovery occurs in most men after cessation, with variable timing 3031
T4DM, Testosterone for Type 2 Diabetes Prevention (Wittert 2021 Lancet D&E) Randomized double-blind placebo-controlled phase 3b trial of testosterone undecanoate plus lifestyle in overweight/obese men with prediabetes or screening-detected diabetes 1007 2 years Testosterone reduced incidence of type 2 diabetes vs lifestyle alone; weight loss and glycemic improvement larger with testosterone 38
TRAVERSE Fracture Substudy (Snyder 2024 NEJM) Pre-specified substudy of TRAVERSE 5204 Mean 3.2 years Higher rate of clinical fractures in the testosterone arm than placebo, counterintuitive given prior T-Trials bone-density gain; emphasizes the difference between BMD and clinical fracture endpoints 39
TRAVERSE Diabetes Substudy (Bhasin 2024 JAMA Intern Med) Pre-specified substudy of TRAVERSE in men with prediabetes — Through TRAVERSE follow-up Testosterone did not reduce progression from prediabetes to type 2 diabetes in this elevated-CV-risk hypogonadal population, contrasts with the T4DM trial's positive effect in a different risk profile 40
TRAVERSE Prostate Risk Substudy (Bhasin 2024 JCEM) Pre-specified substudy of TRAVERSE — Through TRAVERSE follow-up Detailed analysis of prostate-cancer incidence, PSA trajectories, and prostate safety on testosterone vs placebo in hypogonadal men 41
TRAVERSE Anemia Substudy (Pencina 2023 JAMA Netw Open) Pre-specified substudy of TRAVERSE — 12 months Testosterone replacement corrected anemia in hypogonadal men with elevated CV risk; effect size consistent with prior T-Trials anemia substudy 45 42
TRAVERSE Sexual Function Substudy (Pencina 2024 JCEM) Pre-specified substudy of TRAVERSE — Through TRAVERSE follow-up Testosterone improved sexual activity, hypogonadal symptoms, and energy in men with hypogonadism and elevated CV risk, extends Cunningham 2016 T-Trials findings to a higher-CV-risk population 43
T-Trials Sexual Function Substudy (Cunningham 2016 JCEM) T-Trials sexual function substudy 470 12 months Testosterone improved sexual activity, sexual desire, and erectile function vs placebo in older hypogonadal men; effect sizes modest but statistically robust 44
T-Trials Anemia Substudy (Roy 2017 JAMA Intern Med) T-Trials anemia substudy 788 12 months Testosterone corrected unexplained anemia in older men with low testosterone, both anemia of presumed inflammation and unexplained anemia improved on therapy 45
Hudson Individual-Participant-Data Meta-Analysis (Hudson 2022 Lancet Healthy Longevity) IPD and aggregate-data meta-analysis of randomized trials of testosterone in adult men 35 trials, 17,158 participants Up to several years per trial Testosterone treatment was not associated with significant increase in cardiovascular events or all-cause mortality in pooled randomized data, anticipated TRAVERSE result 46
Wu EMAS, Late-Onset Hypogonadism (Wu 2010 NEJM) Prospective observational cohort, European Male Aging Study 3369 Cross-sectional plus longitudinal follow-up Defined the operational symptoms-plus-laboratory criteria for late-onset hypogonadism, three sexual symptoms (low libido, ED, infrequent morning erections) plus total testosterone <11 nmol/L plus free testosterone <220 pmol/L 47
Tajar EMAS, Heterogeneity of Hypogonadism (Tajar 2012 JCEM) EMAS prospective cohort characterization 3369 Cross-sectional plus longitudinal Characterized primary, secondary (hypogonadotropic), and compensated hypogonadism phenotypes, clarified that secondary hypogonadism predominates in obese aging men, primary in lean aging men 48
Travison Harmonized Reference Ranges (Travison 2017 JCEM) Harmonization of total testosterone assays across four cohort studies (CARDIA, EMAS, FHS, Osteoporotic Fractures in Men) Over 9000 men pooled Cross-cohort Harmonized total testosterone reference range 264, 916 ng/dL (9.2, 31.8 nmol/L) in healthy young men, widely adopted lower-bound cutoff for clinical hypogonadism 49
Davis Transdermal Testosterone for Postmenopausal Women (Davis 2008 NEJM) Phase III randomized double-blind placebo-controlled trial of transdermal testosterone in postmenopausal women with HSDD not taking estrogen 814 52 weeks Testosterone 300 μg/day increased the frequency of satisfying sexual events and improved desire and arousal vs placebo; androgenic adverse effects modest and reversible 50
Braunstein Testosterone Patch in Surgical Menopause (Braunstein 2005 Arch Intern Med) RCT of transdermal testosterone in surgically menopausal women with HSDD on stable estrogen 447 24 weeks Testosterone 300 μg/day increased frequency of total satisfying sexual activity and reduced personal distress vs placebo, early supporting evidence in surgical-menopause population 51
Kingsberg Clinical Relevance of Testosterone Patch Benefits (Kingsberg 2007 J Sex Med) Pooled analysis of clinical meaningfulness across testosterone patch HSDD trials — Pooled trial data Defined responder thresholds and clinically meaningful changes for testosterone HSDD trials in women, informs effect-size interpretation 52
Fernández-Balsells Adverse-Effects Meta-Analysis (Fernández-Balsells 2010 JCEM) Systematic review and meta-analysis of randomized testosterone trials 51 studies Pooled Inventoried adverse-event categories, confirmed PSA increase and erythrocytosis signals; insufficient power to confirm or exclude cardiovascular harm 55
Xu Cardiovascular Meta-Analysis (Xu 2013 BMC Medicine) Meta-analysis of randomized testosterone trials with CV outcomes 27 trials, 2994 men Pooled Suggested elevated cardiovascular risk on testosterone vs placebo; methodologically debated, superseded by individual-participant-data and dedicated outcomes trials 56
Borst Injection vs Transdermal Cardiovascular Safety (Borst 2015 Am J Physiol) Meta-analysis stratifying by route of administration — Pooled randomized data Suggested IM injection produced less cardiovascular event excess than transdermal administration, informed pre-TRAVERSE prescribing debate 57
Alexander Cardiovascular Meta-Analysis (Alexander 2017 Am J Med) Updated systematic review of cardiovascular events on exogenous testosterone 39 trials Pooled No statistically significant excess of MACE on testosterone vs placebo in pooled pre-TRAVERSE randomized data, informed FDA mandate for the dedicated TRAVERSE outcomes trial 58
Bachman Testosterone and Hepcidin (Bachman 2014 J Gerontol) Mechanistic study of testosterone's erythropoietic effect — Months Testosterone increases erythropoietin and suppresses hepcidin, raising the EPO-hemoglobin set point, mechanistic basis of clinical erythrocytosis 59
Handelsman Pellet Pharmacokinetics (Handelsman 1990 JCEM) Open-label PK and PD study of subcutaneous testosterone pellets in hypogonadal men — Up to 6 months per pellet cycle Established the PK basis for the 3, 6 month pellet interval; serum testosterone profile with 200, 800 mg pellet doses 67
Kelleher Pellet Release and Site Geometry (Kelleher 2001 Clin Endocrinol; Kelleher 2004 Clin Endocrinol) Clinical PK and explanation analyses of testosterone pellet implants — Months Quantified pellet release rate, duration of action, and effect of implantation-site geometry on extrusion, practical basis for current pellet implantation technique 6869
Traustadóttir Long-Term Testosterone and Aerobic Capacity (Traustadóttir 2018 JCEM) 3-year randomized extension of testosterone supplementation in older men — 36 months Long-term testosterone supplementation attenuated age-related decline in VO2 peak vs placebo, extended-duration efficacy beyond the typical 1-year T-Trials window 70
Valderrábano Testosterone in Prostate Cancer Survivors (Valderrábano 2023 Andrology) Prospective clinical protocol in prostate-cancer survivors with testosterone deficiency — Months Demonstrated cautious replacement protocols can be implemented in selected prostate-cancer survivor populations without consistent biochemical recurrence excess, emerging area of practice 71
WPATH Standards of Care Version 8 (Coleman 2022) International multidisciplinary consensus guideline — Synthesis Defines current best-practice framework for testosterone use in masculinizing gender-affirming care; cross-references Endocrine Society 2017 guideline (Hembree) 5453

Mechanism detail

Detailed Mechanism of Testosterone

Androgen receptor structure. The androgen receptor (AR) is a member of the nuclear receptor superfamily encoded on the X chromosome 61. Like other steroid receptors, it has a modular domain organization, an N-terminal transactivation domain, a central DNA-binding domain with two zinc-finger motifs that recognize androgen-response elements in target-gene promoters, a hinge region, and a C-terminal ligand-binding domain. Unliganded AR resides in the cytoplasm complexed with heat-shock proteins; ligand binding induces conformational change, displacement of chaperones, homodimerization, nuclear translocation, and recruitment of coactivator complexes that drive transcription of androgen-responsive genes 60. Beyond this classical genomic pathway, AR also signals via rapid, nongenomic effects through plasma-membrane-associated complexes that engage kinase cascades (Heinlein 2002 nongenomic).

5α-reductase pathway. In androgen-target tissues including prostate, hair follicle, external genitalia, and skin, testosterone is converted to the more potent agonist dihydrotestosterone (DHT) by 5α-reductase. Two isoforms, type 1 (predominantly liver and skin) and type 2 (predominantly prostate and external genitalia), were cloned and pharmacologically characterized in the early 1990s by Andersson and Jenkins 64. Loss-of-function mutations in 5α-reductase type 2 produce a recognizable disorder of sex development 63. DHT binds AR with greater affinity and slower dissociation than testosterone, amplifying androgen signaling in tissues that express the reductase.

Aromatization to estradiol. Aromatase (CYP19A1) converts testosterone to estradiol and androstenedione to estrone. In men, aromatization occurs in adipose tissue, bone, brain, and the Leydig cells themselves; the estradiol generated locally and systemically mediates a substantial fraction of testosterone's effect on bone density and lipid metabolism. Pharmacologic aromatase suppression in men reproduces specific features of estrogen deficiency despite preserved testosterone 65. The Finkelstein 2013 NEJM goserelin-suppression study with separate testosterone and anastrozole add-back arms is the foundational dissection of which androgenic phenotypes are testosterone-mediated and which are estradiol-mediated 11.

Sex hormone-binding globulin (SHBG) physiology. Circulating testosterone exists in three pools, a tightly bound fraction (~40, 60%) on SHBG, a weakly bound fraction (~40, 60%) on albumin, and a free fraction (~1, 2%) 49. The free hormone hypothesis 66 holds that only unbound steroid is biologically available to enter cells by diffusion; bioavailable testosterone (free plus albumin-bound) is the operational summary clinicians use. SHBG concentration is regulated by hepatic estrogen exposure, thyroid status, insulin signaling, and inflammation; alterations in SHBG (obesity, hyperinsulinemia, hyperthyroidism, hypothyroidism, hepatic disease) drive much of the discrepancy between total and free testosterone clinicians encounter 1.

Intracellular conversion at target tissues. The same circulating testosterone produces tissue-specific effects depending on the local complement of converting enzymes and coregulators. Prostate and skin express 5α-reductase type 2 and convert testosterone to DHT locally, explaining why finasteride and dutasteride attenuate prostate and scalp effects without lowering serum testosterone. Adipose tissue and brain express aromatase, local conversion to estradiol explains testosterone's bone, fat-mass, and some libido effects. Muscle expresses AR but not 5α-reductase at high levels, so muscle anabolism is driven by testosterone directly 49. This tissue-selective intracrinology is the molecular basis for the distinct anabolic versus androgenic phenotypes of androgen action.

Anabolic versus androgenic mechanisms. The anabolic effects (skeletal muscle hypertrophy, lean mass, erythropoiesis, bone formation) are largely AR-mediated effects of testosterone itself in tissues with low 5α-reductase activity, and they are dose-dependent across the physiologic and supraphysiologic range 12. The androgenic effects (prostate growth, sebum production, hair-follicle response, virilization of external genitalia) require local DHT conversion. Erythropoiesis is partially direct (AR-mediated EPO induction in renal interstitial cells) and partially indirect (suppression of hepcidin and increased iron-restricted erythropoiesis; Bachman 2014) 59.

Post-receptor signaling cascades. Genomic AR signaling proceeds via DNA-bound AR-coactivator complexes (including SRC/p160 family, p300/CBP, and tissue-specific factors) that remodel chromatin at androgen-response-element-flanked target genes (Heinlein 2002 coregulators) 61. Nongenomic AR signaling activates phosphatidylinositol 3-kinase / Akt, MAP kinase, and Src-family kinase cascades on a faster timescale and is implicated in muscle hypertrophy and bone-cell survival (Heinlein 2002 nongenomic) 62. The HPG feedback that underlies fertility suppression is a separate hypothalamic loop: GnRH pulsatility from arcuate / preoptic neurons drives LH and FSH; exogenous testosterone (and aromatized estradiol) suppress GnRH pulse amplitude/frequency, reducing LH/FSH and shutting down testicular testosterone synthesis and spermatogenesis 13. Brief pulsatile delivery (intranasal Natesto TID) incompletely suppresses LH and partially preserves spermatogenesis 21.

Pharmacology

Testosterone Pharmacokinetics & Pharmacodynamics

Pharmacokinetics

Bioidentical testosterone has very low oral bioavailability due to extensive first-pass hepatic metabolism, this is why effectively every clinically useful preparation either esterifies the molecule for IM/SC depot delivery, bypasses first-pass via transdermal, buccal, intranasal, or sublingual routes, or uses the undecanoate ester with lymphatic absorption (oral Jatenzo/Tlando) 20.

Injectable esters: cypionate and enanthate have similar pharmacokinetics, peak at approximately 24, 48 hours after IM injection, with serum testosterone returning toward the lower end of normal by 7, 10 days 1922. Twice-weekly or weekly SC dosing reduces peak-trough variability. Propionate has a much shorter ester half-life requiring every-1, 3-day dosing. Undecanoate IM (Aveed) gives a long flat profile over approximately 10 weeks 18.

Transdermal gels reach near-steady-state within 2, 3 days of daily application, with mid-application serum testosterone in the mid-normal range and modest day-to-day variability 14 15. Buccal Striant produces serum levels within 30 minutes of application and sustained physiologic levels with twice-daily dosing 16 17. Intranasal Natesto produces brief serum pulses with each TID dose, a profile that preserves LH/FSH and spermatogenesis better than other formulations 21. Pellets (Testopel) release over 3, 6 months.

Pharmacodynamics

Pharmacodynamic effects are dose-dependent 12. Replacement to mid-normal range raises lean body mass, strength, hemoglobin, and bone mineral density, while reducing fat mass; effects on libido and erectile function depend on bringing serum testosterone above an individual threshold. Estradiol (derived by aromatization) is the principal mediator of testosterone's effects on fat mass and on some bone and sexual-function endpoints 11 13.

Hematologic pharmacodynamics: testosterone increases erythropoiesis directly via the androgen receptor and indirectly via suppression of hepcidin. The dose-response is steeper in older than younger men 24, which underlies the erythrocytosis-risk warning. HPG-axis pharmacodynamics: exogenous testosterone suppresses LH and FSH, with downstream suppression of intratesticular testosterone and spermatogenesis 13. The exception is brief-pulse intranasal Natesto, which incompletely suppresses LH and partially preserves spermatogenesis 21.

Comparative formulations

Comparing Testosterone Formulations

Choice of formulation balances pharmacokinetic preference, fertility goals, patient comfort, and the manufactured-product range. IM/SC esters (cypionate, enanthate) are the historical workhorses, flexible, inexpensive, but with peak-trough variability that some patients feel. Long-acting undecanoate IM (Aveed) gives 10-week intervals but requires REMS-monitored injection. Transdermal gels avoid injections but require attention to transfer and produce smaller peak-trough swings 14. Buccal Striant 16 is twice-daily without injections 17. Intranasal Natesto 21 is the most fertility-sparing FDA-approved route. Xyosted 22 is a weekly self-administered SC auto-injection. Pellets (Testopel) give 3, 6 month duration but require an office procedure.

Compounded preparations expand the route palette: scrotal cream (higher absorption per mg than non-scrotal), troche (sublingual/buccal alternative to manufactured Striant), custom-concentration transdermal cream, and female-physiologic-strength preparations for HSDD 1517. Compounded SC cypionate or enanthate is widely prescribed for men who prefer weekly SC dosing at non-Xyosted strengths or in oils other than the manufactured product's vehicle 2334.

RonanRx compounds these preparations on patient-specific prescription, with documented clinical reason for compounding 15. The pharmacist review confirms the prescribed formulation is responsive to a documented patient-specific need and is not routine substitution for a manufactured product.

Storage

Testosterone Storage and Handling

Compounded injectable testosterone preparations in oil are stored at controlled room temperature (USP definition 20, 25°C, with allowed excursions 15, 30°C) protected from light. Refrigeration is generally not required for ester-in-oil preparations and may cause crystallization of higher-concentration cypionate or enanthate solutions. Beyond-use dating follows USP <797> for sterile compounded preparations.

Transdermal creams, troches, intranasal preparations, and other non-sterile compounded forms are stored per the dispensing label, typically at controlled room temperature, with beyond-use dating per USP <795> non-sterile compounding standards 3736. Light-resistant packaging is preferred for testosterone-containing preparations.

RonanRx operations

Testosterone Compounding & Operations

503A compounding

RonanRx compounds testosterone preparations under 503A on patient-specific prescriptions. Sterile injectable preparations (compounded SC/IM cypionate, enanthate, propionate) follow USP General Chapter <797> for sterile pharmaceutical compounding, with documented active-ingredient sourcing (USP/NF grade), sterility and endotoxin testing per applicable risk-level requirements, gravimetric/volumetric verification, and full lot traceability 3637. Non-sterile preparations (troches, transdermal creams, oral capsules, intranasal vehicles) follow USP General Chapter <795>.

Testosterone is a Schedule III controlled substance under the Controlled Substances Act. RonanRx maintains DEA-registered controlled-substance handling: locked storage, biennial inventory, dispensing records retained per state and federal requirements, and limits on refills and transfer per Schedule III rules 35. Each prescription is verified for prescriber DEA registration and patient identity before dispensing.

Pharmacist review

Each prescription for compounded testosterone undergoes pharmacist review prior to dispensing. The review confirms: a documented patient-specific clinical reason for the compounded preparation (formulation/route not in the manufactured market, ester preference, custom strength, excipient sensitivity); diagnostic basis consistent with the Endocrine Society 2018 (Bhasin) and AUA 2018 (Mulhall) guideline framework; absence of contraindications (active prostate or breast cancer, pregnancy, uncorrected severe erythrocytosis); confirmation of baseline monitoring (testosterone level, hematocrit, PSA in age-appropriate men); appropriate Schedule III prescription elements 12.

RonanRx does not fill prescriptions for compounded testosterone that read as routine substitution for an available manufactured product without documented clinical rationale, consistent with FDA guidance on compounded copies of approved drugs 34.

Quality and traceability

Testosterone API is sourced from FDA-registered facilities with documented certificates of analysis. Each batch is recorded with lot numbers traceable to API source, compounding date, beyond-use date, and dispensing pharmacist of record. Sterile preparations carry sterility and endotoxin test documentation per USP <797> risk-level requirements 37. Schedule III controlled-substance ordering, receipt, and dispensing records are retained per DEA and state board of pharmacy requirements.

Cold chain

Most compounded testosterone preparations are not cold-chain products. Injectable ester-in-oil preparations and transdermal creams are shipped at controlled room temperature. Patients are instructed to store at room temperature in tightly closed containers, protected from light, and to contact the pharmacy if shipping temperature integrity is in doubt.

FAQ

Frequently Asked Questions About Testosterone

Is compounded testosterone the same as AndroGel or Depo-Testosterone?

No. AndroGel, Depo-Testosterone, Xyosted, Aveed, Natesto, Striant, Testopel, and other branded testosterone products are FDA-approved manufactured products. Compounded preparations are pharmacy-prepared on a patient-specific prescription and are not FDA-approved 34. They are dispensed when a documented patient-specific clinical need is not met by a manufactured product, for example, a specific ester, a custom strength, a troche, a scrotal cream, or an excipient-substituted preparation 35.

When does compounded testosterone make clinical sense?

Common documented reasons include: a route the manufactured market does not provide (compounded transdermal cream at a non-manufactured concentration, troche, scrotal cream); a strength the manufactured market does not provide (female-physiologic doses for HSDD; intermediate doses for titration); an ester preference (propionate, custom-concentration cypionate or enanthate); or excipient sensitivity. Routine substitution of compounded for manufactured product without a documented reason is not appropriate 341.

Will testosterone affect my fertility?

Yes. Exogenous testosterone suppresses pituitary LH and FSH, which shuts down endogenous testicular testosterone production and spermatogenesis. Men on TRT have markedly reduced fertility while on therapy. Recovery is typical after cessation but timing varies (McBride 2016; Ramasamy 2015) 30. The intranasal Natesto formulation partially preserves spermatogenesis because of its brief-pulse pharmacokinetics (Rogol 2016) 21. Men with fertility goals should discuss alternatives (HCG, clomiphene, SERMs) with their prescriber before starting TRT 31.

What does TRAVERSE tell us about cardiovascular risk?

TRAVERSE (Lincoff 2023 NEJM, n=5246) was the FDA-mandated cardiovascular outcomes trial in men with hypogonadism plus elevated CV risk 8. Testosterone was non-inferior to placebo for major adverse cardiovascular events over a mean 33-month follow-up 9. The treated arm had higher rates of atrial fibrillation, acute kidney injury, and pulmonary embolism. TRAVERSE clarified but did not eliminate cardiovascular-risk discussion; older signals from TOM (Basaria 2010) in frail men and observational data (Vigen 2013) remain part of shared decision-making 10.

What about prostate cancer risk?

Testosterone replacement is contraindicated in men with active prostate cancer or breast cancer. In men without active prostate cancer, the contemporary evidence (Calof 2005 meta-analysis; T-Trials; Morgentaler 2019 review) does not support a consistent excess of detected prostate cancer with replacement therapy, though PSA may rise modestly 2632. PSA monitoring at baseline and on therapy in age-appropriate men is standard 1.

Can women take testosterone?

Yes, testosterone is a normal physiologic hormone in women, and post-menopausal HSDD is the best-supported off-label indication. The Global Consensus Position Statement (Davis 2019), Islam 2019 Lancet D&E meta-analysis, and Endocrine Society 2014 women's guideline (Wierman) support short-term physiologic-dose use 272829. No FDA-approved testosterone product exists for women in the United States; compounded female-strength preparations or off-label fractional dosing of male products are used in practice. Long-term safety beyond 24 months is not established.

Why does my hematocrit need to be checked?

Testosterone is a physiologic erythropoietic stimulus and produces a dose-dependent rise in hematocrit (Coviello 2008) 24. At higher hematocrits (commonly above 54%) the prescribing clinician will reduce dose, lengthen the dosing interval, or temporarily hold therapy per the framework reviewed by Ohlander 2018 25.

Does RonanRx sell testosterone directly to patients?

No. Testosterone is a Schedule III controlled substance dispensed only on a patient-specific prescription written by a licensed prescriber for an identified patient, with pharmacist review before dispensing. RonanRx is not a direct-to-consumer storefront 35.

Clinician resource

Download the Testosterone Clinical Monograph (PDF)

The full white paper covers every section on this page plus chemical identity, evidence grading, indication-by-indication summaries, research gaps, and reference appendix. Suitable for sharing with prescribing doctors and pharmacist reviewers.

Download information packet ↓

References

References

  1. [bhasin2018endo] Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, Snyder PJ, Swerdloff RS, Wu FC, Yialamas MA. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism. 2018. PMID 29562364. (accessed 2026-05-11)
  2. [mulhall2018aua] Mulhall JP, Trost LW, Brannigan RE, Kurtz EG, Redmon JB, Chiles KA, Lightner DJ, Miner MM, Murad MH, Nelson CJ, Platz EA, Ramanathan LV, Lewis RW. Evaluation and Management of Testosterone Deficiency: AUA Guideline. Journal of Urology. 2018. PMID 29601923. (accessed 2026-05-11)
  3. [snyder2016ttrials] Snyder PJ, Bhasin S, Cunningham GR, Matsumoto AM, Stephens-Shields AJ, Cauley JA, Gill TM, Barrett-Connor E, Swerdloff RS, Wang C, Ensrud KE, Lewis CE, Farrar JT, Cella D, Rosen RC, Pahor M, Crandall JP, Molitch ME, Cifelli D, Dougar D, Fluharty L, Resnick SM, Storer TW, Anton S, Basaria S, Diem SJ, Hou X, Mohler ER 3rd, Parsons JK, Wenger NK, Zeldow B, Landis JR, Ellenberg SS. Effects of Testosterone Treatment in Older Men. New England Journal of Medicine. 2016. PMID 26886521. (accessed 2026-05-11)
  4. [snyder2017bone] Snyder PJ, Kopperdahl DL, Stephens-Shields AJ, Ellenberg SS, Cauley JA, Ensrud KE, Lewis CE, Barrett-Connor E, Schwartz AV, Lee DC, Bhasin S, Cunningham GR, Gill TM, Matsumoto AM, Swerdloff RS, Basaria S, Diem SJ, Wang C, Hou X, Cifelli D, Dougar D, Zeldow B, Bauer DC, Keaveny TM. Effect of Testosterone Treatment on Volumetric Bone Density and Strength in Older Men With Low Testosterone: A Controlled Clinical Trial. JAMA Internal Medicine. 2017. PMID 28241231. (accessed 2026-05-11)
  5. [budoff2017plaque] Budoff MJ, Ellenberg SS, Lewis CE, Mohler ER 3rd, Wenger NK, Bhasin S, Barrett-Connor E, Swerdloff RS, Stephens-Shields A, Cauley JA, Crandall JP, Cunningham GR, Ensrud KE, Gill TM, Matsumoto AM, Molitch ME, Nakanishi R, Nezarat N, Matsumoto S, Hou X, Basaria S, Diem SJ, Wang C, Cifelli D, Snyder PJ. Testosterone Treatment and Coronary Artery Plaque Volume in Older Men With Low Testosterone. JAMA. 2017. PMID 28241355. (accessed 2026-05-11)
  6. [resnick2017cognition] Resnick SM, Matsumoto AM, Stephens-Shields AJ, Ellenberg SS, Gill TM, Shumaker SA, Pleasants DD, Barrett-Connor E, Bhasin S, Cauley JA, Cella D, Crandall JP, Cunningham GR, Ensrud KE, Farrar JT, Lewis CE, Molitch ME, Pahor M, Swerdloff RS, Cifelli D, Anton S, Basaria S, Diem SJ, Wang C, Hou X, Snyder PJ. Testosterone Treatment and Cognitive Function in Older Men With Low Testosterone and Age-Associated Memory Impairment. JAMA. 2017. PMID 28241356. (accessed 2026-05-11)
  7. [snyder2018lessons] Snyder PJ, Bhasin S, Cunningham GR, Matsumoto AM, Stephens-Shields AJ, Cauley JA, Gill TM, Barrett-Connor E, Swerdloff RS, Wang C, Ensrud KE, Lewis CE, Farrar JT, Cella D, Rosen RC, Pahor M, Crandall JP, Molitch ME, Resnick SM, Budoff M, Mohler ER 3rd, Wenger NK, Cohen HJ, Schrier S, Keaveny TM, Kopperdahl D, Lee D, Cifelli D, Ellenberg SS. Lessons From the Testosterone Trials. Endocrine Reviews. 2018. PMID 29522088. (accessed 2026-05-11)
  8. [lincoff2023traverse] Lincoff AM, Bhasin S, Flevaris P, Mitchell LM, Basaria S, Boden WE, Cunningham GR, Granger CB, Khera M, Thompson IM Jr, Wang Q, Wolski K, Davey D, Kalahasti V, Khan N, Miller MG, Snabes MC, Chan A, Dubcenco E, Li X, Yi T, Huang B, Pencina KM, Travison TG, Nissen SE. Cardiovascular Safety of Testosterone-Replacement Therapy. New England Journal of Medicine. 2023. PMID 37326322. (accessed 2026-05-11)
  9. [basaria2010tom] Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, Eder R, Tennstedt S, Ulloor J, Zhang A, Choong K, Lakshman KM, Mazer NA, Miciek R, Krasnoff J, Elmi A, Knapp PE, Brooks B, Appleman E, Aggarwal S, Bhasin G, Hede-Brierley L, Bhatia A, Collins L, LeBrasseur N, Fiore LD, Bhasin S. Adverse events associated with testosterone administration. New England Journal of Medicine. 2010. PMID 20592293. (accessed 2026-05-11)
  10. [vigen2013jama] Vigen R, O'Donnell CI, Barón AE, Grunwald GK, Maddox TM, Bradley SM, Barqawi A, Woning G, Wierman ME, Plomondon ME, Rumsfeld JS, Ho PM. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013. PMID 24193080. (accessed 2026-05-11)
  11. [finkelstein2013gonadal] Finkelstein JS, Lee H, Burnett-Bowie SA, Pallais JC, Yu EW, Borges LF, Jones BF, Barry CV, Wulczyn KE, Thomas BJ, Leder BZ. Gonadal steroids and body composition, strength, and sexual function in men. New England Journal of Medicine. 2013. PMID 24024838. (accessed 2026-05-11)
  12. [bhasin1996supra] Bhasin S, Storer TW, Berman N, Callegari C, Clevenger B, Phillips J, Bunnell TJ, Tricker R, Shirazi A, Casaburi R. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. New England Journal of Medicine. 1996. PMID 8637535. (accessed 2026-05-11)
  13. [bhasin2001dose] Bhasin S, Woodhouse L, Casaburi R, Singh AB, Bhasin D, Berman N, Chen X, Yarasheski KE, Magliano L, Dzekov C, Dzekov J, Bross R, Phillips J, Sinha-Hikim I, Shen R, Storer TW. Testosterone dose-response relationships in healthy young men. American Journal of Physiology - Endocrinology and Metabolism. 2001. PMID 11701431. (accessed 2026-05-11)
  14. [wang2000gel] Wang C, Swerdloff RS, Iranmanesh A, Dobs A, Snyder PJ, Cunningham G, Matsumoto AM, Weber T, Berman N; Testosterone Gel Study Group. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. Journal of Clinical Endocrinology & Metabolism. 2000. PMID 10946892. (accessed 2026-05-11)
  15. [swerdloff2000pk] Swerdloff RS, Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, Snyder PJ, Weber T, Longstreth J, Berman N. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. Journal of Clinical Endocrinology & Metabolism. 2000. PMID 11134099. (accessed 2026-05-11)
  16. [wang2004striant] Wang C, Swerdloff R, Kipnes M, Matsumoto AM, Dobs AS, Cunningham G, Katznelson L, Weber TJ, Friedman TC, Snyder P, Danoff TM. New testosterone buccal system (Striant) delivers physiological testosterone levels: pharmacokinetics study in hypogonadal men. Journal of Clinical Endocrinology & Metabolism. 2004. PMID 15292312. (accessed 2026-05-11)
  17. [korbonits2004striant] Korbonits M, Slawik M, Cullen D, Ross RJ, Stalla G, Schneider H, Reincke M, Bouloux PM, Grossman AB. A comparison of a novel testosterone bioadhesive buccal system, Striant, with a testosterone adhesive patch in hypogonadal males. Journal of Clinical Endocrinology & Metabolism. 2004. PMID 15126518. (accessed 2026-05-11)
  18. [behre1999tu] Behre HM, Abshagen K, Oettel M, Hübler D, Nieschlag E. Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies. European Journal of Endocrinology. 1999. PMID 10229906. (accessed 2026-05-11)
  19. [minnemann2008undecanoate] Minnemann T, Schubert M, Hübler D, Gouni-Berthold I, Freude S, Schumann C, Oettel M, Ernst M, Mellinger U, Sommer F, Krone W, Jockenhövel F. Comparison of a new long-acting testosterone undecanoate formulation vs testosterone enanthate for intramuscular androgen therapy in male hypogonadism. Journal of Endocrinological Investigation. 2008. PMID 18852533. (accessed 2026-05-11)
  20. [saad2007undecanoate] Saad F, Kamischke A, Yassin A, Zitzmann M, Schubert M, Jockenhel F, Behre HM, Gooren L, Nieschlag E. More than eight years' hands-on experience with the novel long-acting parenteral testosterone undecanoate. Asian Journal of Andrology. 2007. PMID 17486268. (accessed 2026-05-11)
  21. [rogol2016natesto] Rogol AD, Tkachenko N, Bryson N. Natesto™ , a novel testosterone nasal gel, normalizes androgen levels in hypogonadal men.. Andrology. 2016. PMID 26695758. (accessed 2026-05-11)
  22. [kaminetsky2019xyosted52] Kaminetsky JC, McCullough A, Hwang K, Jaffe JS, Wang C, Swerdloff RS. A 52-Week Study of Dose Adjusted Subcutaneous Testosterone Enanthate in Oil Self-Administered via Disposable Auto-Injector. Journal of Urology. 2019. PMID 30296416. (accessed 2026-05-11)
  23. [gittelman2019xyosted] Gittelman M, Jaffe JS, Kaminetsky JC. Safety of a New Subcutaneous Testosterone Enanthate Auto-Injector: Results of a 26-Week Study. Journal of Sexual Medicine. 2019. PMID 31551193. (accessed 2026-05-11)
  24. [coviello2008erythro] Coviello AD, Kaplan B, Lakshman KM, Chen T, Singh AB, Bhasin S. Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. Journal of Clinical Endocrinology & Metabolism. 2008. PMID 18160461. (accessed 2026-05-11)
  25. [ohlander2018erythro] Ohlander SJ, Varghese B, Pastuszak AW. Erythrocytosis Following Testosterone Therapy. Sexual Medicine Reviews. 2018. PMID 28526632. (accessed 2026-05-11)
  26. [calof2005ae] Calof OM, Singh AB, Lee ML, Kenny AM, Urban RJ, Tenover JL, Bhasin S. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. Journals of Gerontology Series A: Biological Sciences and Medical Sciences. 2005. PMID 16339333. (accessed 2026-05-11)
  27. [davis2019consensus] Davis SR, Baber R, Panay N, Bitzer J, Perez SC, Islam RM, Kaunitz AM, Kingsberg SA, Lambrinoudaki I, Liu J, Parish SJ, Pinkerton J, Rymer J, Simon JA, Vignozzi L, Wierman ME. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. Journal of Sexual Medicine. 2019. PMID 31488288. (accessed 2026-05-11)
  28. [islam2019women] Islam RM, Bell RJ, Green S, Page MJ, Davis SR. Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. Lancet Diabetes & Endocrinology. 2019. PMID 31353194. (accessed 2026-05-11)
  29. [wierman2014women] Wierman ME, Arlt W, Basson R, Davis SR, Miller KK, Murad MH, Rosner W, Santoro N. Androgen therapy in women: a reappraisal: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism. 2014. PMID 25279570. (accessed 2026-05-11)
  30. [mcbride2016recovery] McBride JA, Coward RM. Recovery of spermatogenesis following testosterone replacement therapy or anabolic-androgenic steroid use. Asian Journal of Andrology. 2016. PMID 26908067. (accessed 2026-05-11)
  31. [ramasamy2015fertility] Ramasamy R, Armstrong JM, Lipshultz LI. Preserving fertility in the hypogonadal patient: an update. Asian Journal of Andrology. 2015. PMID 25337850. (accessed 2026-05-11)
  32. [morgentaler2019prostate] Morgentaler A, Caliber M. Safety of testosterone therapy in men with prostate cancer. Expert Opinion on Drug Safety. 2019. PMID 31495240. (accessed 2026-05-11)
  33. [nieschlag2006age] Nieschlag E. Testosterone treatment comes of age: new options for hypogonadal men. Clinical Endocrinology. 2006. PMID 16918944. (accessed 2026-05-11)
  34. [fda_essentially_a_copy] U.S. Food and Drug Administration. Compounded Drug Products That Are Essentially Copies of Approved Drug Products Under Section 503A of the Federal Food, Drug, and Cosmetic Act — Guidance for Industry. FDA Guidance for Industry. 2018. https://www.fda.gov/media/98973/download (accessed 2026-05-11)
  35. [fda503a] U.S. Food and Drug Administration. Section 503A of the Federal Food, Drug, and Cosmetic Act. 2024. https://www.fda.gov/drugs/human-drug-compounding/section-503a-federal-food-drug-and-cosmetic-act (accessed 2026-05-11)
  36. [usp_795] United States Pharmacopeia. USP General Chapter <795> Pharmaceutical Compounding — Nonsterile Preparations. USP Compounding Compendium. 2024. https://www.usp.org/compounding/general-chapter-795 (accessed 2026-05-11)
  37. [usp_797] United States Pharmacopeia. USP General Chapter <797> Pharmaceutical Compounding — Sterile Preparations. USP Compounding Compendium. 2024. https://www.usp.org/compounding/general-chapter-797 (accessed 2026-05-11)
  38. [wittert2021t4dm] Wittert G, Bracken K, Robledo KP, Grossmann M, Yeap BB, Handelsman DJ, Stuckey B, Conway A, Inder W, McLachlan R, Allan C, Jesudason D, Fui MNT, Hague W, Jenkins A, Daniel M, Gebski V, Keech A. Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial. Lancet Diabetes & Endocrinology. 2021. PMID 33338415. (accessed 2026-05-11)
  39. [snyder2024fracture] Snyder PJ, Bauer DC, Ellenberg SS, Cauley JA, Buhr KA, Bhasin S, Miller MG, Khan NS, Li X, Nissen SE. Testosterone Treatment and Fractures in Men with Hypogonadism. New England Journal of Medicine. 2024. PMID 38231621. (accessed 2026-05-11)
  40. [bhasin2024diabetes] Bhasin S, Lincoff AM, Nissen SE, Wannemuehler K, McDonnell ME, Khera M, Snabes MC, Li X, Pencina KM, Travison TG. Effect of Testosterone on Progression From Prediabetes to Diabetes in Men With Hypogonadism: A Substudy of the TRAVERSE Randomized Clinical Trial. JAMA Internal Medicine. 2024. PMID 38315466. (accessed 2026-05-11)
  41. [bhasin2024prostate] Bhasin S, Travison TG, Pencina KM, O'Leary M, Cunningham GR, Lincoff AM, Nissen SE, Lucia MS, Preston MA, Khera M, Khan N, Snabes MC, Li X, Tangen CM, Buhr KA, Ellenberg SS, Thompson IM Jr. Prostate Risk and Monitoring During Testosterone Replacement Therapy. Journal of Clinical Endocrinology & Metabolism. 2024. PMID 38753865. (accessed 2026-05-11)
  42. [pencina2023anemia] Pencina KM, Travison TG, Cunningham GR, Lincoff AM, Nissen SE, Khera M, Miller MG, Flevaris P, Li X, Wannemuehler K, Bhasin S. Efficacy of Testosterone Replacement Therapy in Correcting Anemia in Men With Hypogonadism: A Randomized Clinical Trial. JAMA Network Open. 2023. PMID 37889486. (accessed 2026-05-11)
  43. [pencina2024sexfn] Pencina KM, Travison TG, Artz AS, Lincoff AM, Nissen SE, Flevaris P, Chan A, Li X, Diegel O, Wannemuehler K, Khera M, Bhasin S. Effect of Testosterone Replacement Therapy on Sexual Function and Hypogonadal Symptoms in Men with Hypogonadism. Journal of Clinical Endocrinology & Metabolism. 2024. PMID 37589949. (accessed 2026-05-11)
  44. [cunningham2016sexfn] Cunningham GR, Stephens-Shields AJ, Rosen RC, Wang C, Bhasin S, Matsumoto AM, Parsons JK, Gill TM, Molitch ME, Farrar JT, Cella D, Barrett-Connor E, Cauley JA, Cifelli D, Crandall JP, Ensrud KE, Gallagher L, Zeldow B, Lewis CE, Pahor M, Swerdloff RS, Hou X, Anton S, Basaria S, Diem SJ, Tabatabaie V, Ellenberg SS, Snyder PJ. Testosterone Treatment and Sexual Function in Older Men With Low Testosterone Levels. Journal of Clinical Endocrinology & Metabolism. 2016. PMID 27355400. (accessed 2026-05-11)
  45. [roy2017anemia] Roy CN, Snyder PJ, Stephens-Shields AJ, Artz AS, Bhasin S, Cohen HJ, Farrar JT, Gill TM, Zeldow B, Cella D, Barrett-Connor E, Cauley JA, Crandall JP, Cunningham GR, Ensrud KE, Lewis CE, Matsumoto AM, Molitch ME, Pahor M, Swerdloff RS, Cifelli D, Hou X, Resnick SM, Walston JD, Anton S, Basaria S, Diem SJ, Wang C, Schrier SL, Ellenberg SS. Association of Testosterone Levels With Anemia in Older Men: A Controlled Clinical Trial. JAMA Internal Medicine. 2017. PMID 28241237. (accessed 2026-05-11)
  46. [hudson2022ipd] Hudson J, Cruickshank M, Quinton R, Aucott L, Aceves-Martins M, Gillies K, Bhattacharya S, Boachie C, Fraser C, Brazzelli M, Jayasena CN. Adverse cardiovascular events and mortality in men during testosterone treatment: an individual patient and aggregate data meta-analysis. Lancet Healthy Longevity. 2022. PMID 35711614. (accessed 2026-05-11)
  47. [wu2010emas] Wu FC, Tajar A, Beynon JM, Pye SR, Silman AJ, Finn JD, O'Neill TW, Bartfai G, Casanueva FF, Forti G, Giwercman A, Han TS, Kula K, Lean ME, Pendleton N, Punab M, Boonen S, Vanderschueren D, Labrie F, Huhtaniemi IT; EMAS Group. Identification of late-onset hypogonadism in middle-aged and elderly men. New England Journal of Medicine. 2010. PMID 20554979. (accessed 2026-05-11)
  48. [tajar2012emas] Tajar A, Huhtaniemi IT, O'Neill TW, Finn JD, Pye SR, Lee DM, Bartfai G, Boonen S, Casanueva FF, Forti G, Giwercman A, Han TS, Kula K, Labrie F, Lean ME, Pendleton N, Punab M, Vanderschueren D, Wu FC; EMAS Group. Characteristics of androgen deficiency in late-onset hypogonadism: results from the European Male Aging Study (EMAS). Journal of Clinical Endocrinology & Metabolism. 2012. PMID 22419720. (accessed 2026-05-11)
  49. [travison2017refrange] Travison TG, Vesper HW, Orwoll E, Wu F, Kaufman JM, Wang Y, Lapauw B, Fiers T, Matsumoto AM, Bhasin S. Harmonized Reference Ranges for Circulating Testosterone Levels in Men of Four Cohort Studies in the United States and Europe. Journal of Clinical Endocrinology & Metabolism. 2017. PMID 28324103. (accessed 2026-05-11)
  50. [davis2008nejm] Davis SR, Moreau M, Kroll R, Bouchard C, Panay N, Gass M, Braunstein GD, Hirschberg AL, Rodenberg C, Pack S, Koch H, Moufarege A, Studd J; APHRODITE Study Team. Testosterone for low libido in postmenopausal women not taking estrogen. New England Journal of Medicine. 2008. PMID 18987368. (accessed 2026-05-11)
  51. [braunstein2005patch] Braunstein GD, Sundwall DA, Katz M, Shifren JL, Buster JE, Simon JA, Bachman G, Aguirre OA, Lucas JD, Rodenberg C, Buch A, Watts NB. Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Archives of Internal Medicine. 2005. PMID 16043675. (accessed 2026-05-11)
  52. [kingsberg2007benefit] Kingsberg S. Evaluation of the clinical relevance of benefits associated with transdermal testosterone treatment in postmenopausal women with hypoactive sexual desire disorder. Journal of Sexual Medicine. 2007. PMID 17627745. (accessed 2026-05-11)
  53. [hembree2017transgender] Hembree WC, Cohen-Kettenis PT, Gooren L, Hannema SE, Meyer WJ, Murad MH, Rosenthal SM, Safer JD, Tangpricha V, T'Sjoen GG. Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism. 2017. PMID 28945902. (accessed 2026-05-11)
  54. [coleman2022wpath] Coleman E, Radix AE, Bouman WP, Brown GR, de Vries ALC, Deutsch MB, Ettner R, Fraser L, Goodman M, Green J, Hancock AB, Johnson TW, Karasic DH, Knudson GA, Leibowitz SF, Meyer-Bahlburg HFL, Monstrey SJ, Motmans J, Nahata L, Nieder TO, Reisner SL, Richards C, Schechter LS, Tangpricha V, Tishelman AC, Van Trotsenburg MAA, Winter S, Ducheny K, Adams NJ, Adrián TM, Allen LR, Azul D, Bagga H, Başar K, Bathory DS, Belinky JJ, Berg DR, Berli JU, Bluebond-Langner RO, Bouman MB, Bowers ML, Brassard PJ, Byrne J, Capitán L, Cargill CJ, Carswell JM, Chang SC, Chelvakumar G, Corneil T, Dalke KB, De Cuypere G, de Vries E, Den Heijer M, Devor AH, Dhejne C, D'Marco A, Edmiston EK, Edwards-Leeper L, Ehrbar R, Ehrensaft D, Eisfeld J, Elaut E, Erickson-Schroth L, Feldman JL, Fisher AD, Garcia MM, Gijs L, Green SE, Hall BP, Hardy TLD, Irwig MS, Jacobs LA, Janssen AC, Johnson K, Klink DT, Kreukels BPC, Kuper LE, Kvach EJ, Malouf MA, Massey R, Mazur T, McLachlan C, Morrison SD, Mosser SW, Neira PM, Nygren U, Oates JM, Obedin-Maliver J, Pagkalos G, Patton J, Phanuphak N, Rachlin K, Reed T, Rider GN, Ristori J, Robbins-Cherry S, Roberts SA, Rodriguez-Wallberg KA, Rosenthal SM, Sabir K, Safer JD, Silva AB, Spencer K, St Amand C, Steensma TD, Strang JF, Taylor GB, Tilleman K, Tolentino TF, Vermeir E, Vlot M, Whelan E, Zwickl S. Standards of Care for the Health of Transgender and Gender Diverse People, Version 8. International Journal of Transgender Health. 2022. PMID 36238954. (accessed 2026-05-11)
  55. [fernandez2010meta] Fernández-Balsells MM, Murad MH, Lane M, Lampropulos JF, Albuquerque F, Mullan RJ, Agrwal N, Elamin MB, Gallegos-Orozco JF, Wang AT, Erwin PJ, Bhasin S, Montori VM. Clinical review 1: Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. Journal of Clinical Endocrinology & Metabolism. 2010. PMID 20525906. (accessed 2026-05-11)
  56. [xu2013meta] Xu L, Freeman G, Cowling BJ, Schooling CM. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Medicine. 2013. PMID 23597181. (accessed 2026-05-11)
  57. [borst2015meta] Borst SE, Yarrow JF. Injection of testosterone may be safer and more effective than transdermal administration for combating loss of muscle and bone in older men. American Journal of Physiology - Endocrinology and Metabolism. 2015. PMID 25898953. (accessed 2026-05-11)
  58. [alexander2017meta] Alexander GC, Iyer G, Lucas E, Lin D, Singh S. Cardiovascular Risks of Exogenous Testosterone Use Among Men: A Systematic Review and Meta-Analysis. American Journal of Medicine. 2017. PMID 27751897. (accessed 2026-05-11)
  59. [bachman2014hepcidin] Bachman E, Travison TG, Basaria S, Davda MN, Guo W, Li M, Connor Westfall J, Bae H, Gordeuk V, Bhasin S. Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: evidence for a new erythropoietin/hemoglobin set point. Journals of Gerontology Series A: Biological Sciences and Medical Sciences. 2014. PMID 24158761. (accessed 2026-05-11)
  60. [mooradian1987androgens] Mooradian AD, Morley JE, Korenman SG. Biological actions of androgens. Endocrine Reviews. 1987. PMID 3549275. (accessed 2026-05-11)
  61. [heinlein2002coregulators] Heinlein CA, Chang C. Androgen receptor (AR) coregulators: an overview. Endocrine Reviews. 2002. PMID 11943742. (accessed 2026-05-11)
  62. [heinlein2002nongenomic] Heinlein CA, Chang C. The roles of androgen receptors and androgen-binding proteins in nongenomic androgen actions. Molecular Endocrinology. 2002. PMID 12351684. (accessed 2026-05-11)
  63. [andersson1991reductase] Andersson S, Berman DM, Jenkins EP, Russell DW. Deletion of steroid 5 alpha-reductase 2 gene in male pseudohermaphroditism. Nature. 1991. PMID 1944596. (accessed 2026-05-11)
  64. [jenkins1992reductase] Jenkins EP, Andersson S, Imperato-McGinley J, Wilson JD, Russell DW. Genetic and pharmacological evidence for more than one human steroid 5 alpha-reductase. Journal of Clinical Investigation. 1992. PMID 1345916. (accessed 2026-05-11)
  65. [mauras2000estrogen] Mauras N, O'Brien KO, Klein KO, Hayes V. Estrogen suppression in males: metabolic effects. Journal of Clinical Endocrinology & Metabolism. 2000. PMID 10902781. (accessed 2026-05-11)
  66. [mendel1989free] Mendel CM. The free hormone hypothesis: a physiologically based mathematical model. Endocrine Reviews. 1989. PMID 2673754. (accessed 2026-05-11)
  67. [handelsman1990pellet] Handelsman DJ, Conway AJ, Boylan LM. Pharmacokinetics and pharmacodynamics of testosterone pellets in man. Journal of Clinical Endocrinology & Metabolism. 1990. PMID 2115044. (accessed 2026-05-11)
  68. [kelleher2001pellet] Kelleher S, Turner L, Howe C, Conway AJ, Handelsman DJ. Influence of implantation site and track geometry on the extrusion rate and pharmacology of testosterone implants. Clinical Endocrinology. 2001. PMID 11678837. (accessed 2026-05-11)
  69. [kelleher2004pellet] Kelleher S, Howe C, Conway AJ, Handelsman DJ. Testosterone release rate and duration of action of testosterone pellet implants. Clinical Endocrinology. 2004. PMID 15049955. (accessed 2026-05-11)
  70. [traustadottir2018aerobic] Traustadóttir T, Harman SM, Tsitouras P, Pencina KM, Li Z, Travison TG, Eder R, Miciek R, McKinnon J, Woodbury E, Basaria S, Bhasin S, Storer TW. Long-Term Testosterone Supplementation in Older Men Attenuates Age-Related Decline in Aerobic Capacity. Journal of Clinical Endocrinology & Metabolism. 2018. PMID 29846604. (accessed 2026-05-11)
  71. [valderrabano2023prostate] Valderrábano RJ, Pencina K, Storer TW, Reid KF, Kibel AS, Burnett AL, Huang G, Dreyfus J, Wilson L, Latham N, Beleva YM, Dixon B, Lee H, Bouxsein M, Travison TG, Basaria S. Testosterone replacement in prostate cancer survivors with testosterone deficiency: Study protocol of a randomized controlled trial. Andrology. 2023. PMID 36181480. (accessed 2026-05-11)

How to access

How to Access Testosterone

Compounded Testosterone is dispensed under 503A on a patient-specific prescription. Pick the path that matches where you're starting from.

For doctors

Offer this medication.

A pharmacist will follow up within two business days. We'll cover state availability, supported formulations, and what integration looks like for your clinic.

Offer this medication →

Patient with a doctor

Receive your prescription.

If your doctor has already prescribed Testosterone, sign up so we can prepare and ship your medication. The signup wizard collects intake and connects you to the prescribing workflow.

Sign up →

Patient without a doctor

Find a partner clinic.

RonanRx prescribes through partner clinics — we don't initiate prescriptions on this site. See how the referral works and how to find a clinic in your state that has evaluated patients for Testosterone.

Find a partner clinic →

Related